

35 calcium affinity, or the number of ions bound on aSyn's aggregation propensity, indicating that
36 sequence or post-translation modification (PTM)-specific conformational differences between the N-
37 and C-termini and the specific local environment mediate aggregation propensity instead.
38 Understanding aggregation prone conformations of monomeric aSyn and the environmental
39 conditions they form under will allow us to design new therapeutics targeted to the monomeric
40 protein, to stabilise aSyn in non-aggregation prone conformations, by either preserving long-range
41 interactions between the N- and C-termini or by protecting the N-terminus from exposure.


42

43 **Introduction**

44 In Parkinson's disease (PD) and other synucleinopathies, the monomeric protein alpha synuclein
45 (aSyn) becomes destabilised, misfolds and aggregates into insoluble, highly structured and β -sheet
46 containing fibrils which form part of Lewy bodies (LB) and Lewy neurites (LN)^{1,2}. In its monomeric
47 form, aSyn is a soluble, intrinsically disordered protein (IDP) that is highly flexible and thereby enables
48 plasticity in its function. In particular, it has been proposed that aSyn plays a role in synaptic vesicle
49 recycling and homeostasis in neurons^{3,4}. Transient and dynamic electrostatic and hydrophobic
50 intramolecular interactions maintain aSyn in its soluble monomeric form. These intramolecular
51 interactions are responsible for aSyn's smaller radius of gyration (R_g) than expected for a 140 amino
52 acid residue (aar) unfolded protein and suggest that some residual structure remains⁵. Therefore, the
53 word 'monomer' actually describes a plethora of conformational states which are constantly
54 reconfiguring. These dynamic interactions are heavily influenced by the surrounding environment of
55 aSyn and their disruption can lead to skewing of the ensemble of monomeric conformations⁶. This, in
56 turn, may influence which aggregation competent/incompetent pathways are taken and whether
57 these are subsequently toxic or not. Identifying conformations of aggregation prone monomeric aSyn
58 or the environment that can destabilise monomeric conformations to favour aggregation will aid in
59 the design of anti-aggregation therapeutics to stabilise the native aSyn conformation.

60 aSyn is a characteristic IDP with high opposing charge at its termini and low overall hydrophobicity⁵.
61 Monomeric aSyn has three characteristic main regions; the N-terminus, aar 1-60, which is overall
62 positively charged, the non-amyloid- β component (NAC) region, aar 61-89, is hydrophobic and forms
63 the core of fibrils during aggregation⁷, and the C-terminus, aar 90-140, is a highly negatively charged
64 region which binds metal ions⁸ (Figure 1a). To date, six disease-related mutations have been identified
65 in the *SNCA* gene, encoding the aSyn protein, A30P, E46K, H50Q, G51D, A53T, A53E, which are a
66 hallmark for hereditary autosomal dominant PD and are primarily linked to early age but also late age
67 of onset (H50Q)⁹⁻¹⁵. However, genetic mutations and multiplications of the *SNCA* gene only account
68 for 5-10% of PD cases and the remaining cases are sporadic (idiopathic) and age-related¹⁶. Yet, we still

69 have not identified mechanistically why these mutations lead to early-onset PD, or what triggers
70 misfolding of WT aSyn.



71

72 **Figure 1. Representation of the regions of monomeric aSyn.** (a) Monomeric aSyn is defined by three
73 regions, the N-terminus, aar 1-60 (blue) with an overall charge of +4, contains the familial mutations
74 A30P, E46K, H50Q, G51D, A53E and A53T. The non-Amyloid- β component (NAC) region, aar 61-95
75 (yellow), has an overall charge of -1, is highly hydrophobic and forms the core of fibrils. The C-
76 terminus, aar 96-140 (red), is highly negatively charged with an overall charge of -12. Residue S129 is
77 commonly phosphorylated (pS129) in Lewy bodies, but rarely in soluble aSyn. The calcium binding
78 region (black line) is also found at the C-terminus and spans residues 115-140. (b) Monomeric aSyn is
79 highly dynamic and visits a large conformational space. Interactions between the N- and C-termini and
80 NAC region maintain it in a soluble form.

81 Intramolecular long-range interactions of aSyn have been detected between many different regions
82 of aSyn. Electrostatic interactions, mediated by the positively charged N-terminus and negatively
83 charged C-terminus, as well as hydrophobic interactions between some residues of the C-terminus
84 and NAC region of aSyn, have been identified using a range of techniques including different nuclear
85 magnetic resonance (NMR) techniques, mass spectrometry (MS) and hydrogen-deuterium exchange
86 MS (HDX-MS) ¹⁷⁻²⁵ (for a review see ⁶) (Figure 1b). The importance of these long-range interactions
87 was demonstrated in studies in which charge and hydrophobicity of the protein were altered by
88 mutations, particularly at the C-terminus, leading to differences in aSyn's aggregation propensity ^{2,26-}
89 ²⁸. Reduction of charge also occurs during the binding of metal ions, salt ions or polyamines which
90 leads to shielding of the charged N- and C-termini and which permits more energetically favourable
91 packing ^{8,29}.

92 Furthermore, post-translational modifications (PTM), such as nitration and phosphorylation, also alter
93 aggregation rates of aSyn. In particular, phosphorylation of S129 which increases the negative charge
94 of the C-terminus by the addition of a PO^{4-} group seems to be pertinent in disease as only 4% of
95 monomeric aSyn is phosphorylated, yet 96% of aSyn in LB and LN are phosphorylated³⁰. However, it
96 is not clear whether phosphorylation of S129 is involved in the physiological or pathological function
97 of aSyn, whether it enhances aggregation^{31,32} or retards aggregation³³. In terms of disease association,
98 the presence of aSyn familial mutations leads to different aggregation rates dependent on the
99 mutation. NMR experiments have shown that C-terminus residues are transiently in contact with all
100 six mutation sites at the N-terminus via long-range interactions²³, yet the different mutations lead to
101 differences in levels of solvent exposure, destabilisation, perturbation of the ensemble of conformers
102 and alterations in long-range interactions³⁴⁻³⁷. Identifying conformations or significant long-range
103 interactions that maintain soluble aSyn is critical in understanding what triggers aSyn misfolding, but
104 the difficulty in identifying these long-range interactions and determining the influence of mutations
105 and aggregation prone conformations of aSyn lies in the complexity of sampling an ensemble of
106 dynamic conformations of the monomeric protein.

107 In the current study, we apply a plethora of techniques, including NMR, fast mixing HDX-MS and nano
108 electrospray ionisation ion mobility mass spectrometry (nano ESI-IM-MS) to study the differences in
109 the conformation of aggregation prone and non-aggregation prone monomeric aSyn including
110 phosphorylated aSyn, pS129, and familial aSyn mutants, A30P, E46K, H50Q, G51D, A53T and A53E. To
111 investigate potential differences in residual structure and long-range interactions, we also performed
112 experiments in the presence of calcium to purposefully skew the dynamic ensemble of conformations
113 as calcium binds at the C-terminus and leads to charge neutralisation³⁸. Calcium has been shown to
114 play a role in the physiological and pathological function of aSyn, as calcium binding at the C-terminus
115 of aSyn facilitates interaction with synaptic vesicles and enhances aSyn aggregation rates^{8,39}.
116 Furthermore, calcium-aSyn interaction is physiologically relevant as calcium buffering becomes
117 dysregulated in PD and an increase in cytosolic calcium occurs⁴⁰. We therefore also investigated a
118 panel of C-terminus mutants D115A, D119A and D121A which are within the calcium binding region
119³⁹.

120 We conclude that the perturbation of the long-range interactions upon calcium binding to monomeric
121 aSyn leads to an increase in N-terminal solvent exposure which correlates with aSyn's aggregation
122 propensity. The distribution of monomeric conformations of the aSyn ensemble is different between
123 aSyn variants (e.g. familial mutants, pS129 aSyn) which populate these conformations to a different
124 extent. The finding that different structural conformations can be identified as early as at the

125 monomer level will be crucial in aiding the development of aSyn aggregation inhibitors stabilising
126 native non-aggregation prone structures.

127

128 **Results**


129 **pS129 and D121A have altered monomeric conformations compared to WT aSyn**

130 We first investigated whether long-range interactions mediated by the C-terminus of aSyn were
131 important in modulating monomer conformation and aggregation propensity of aSyn. We compared
132 WT aSyn to post-translationally modified aSyn, phosphorylated at residue serine 129 (pS129) and to a
133 mutant with reduced charge by mutating aspartate (D) to alanine (A) at residue 121 (D121A). This
134 mutant was chosen from a panel of C-terminus D to A mutants, 115, 119 and 121, which reside in the
135 region of divalent and trivalent cation binding sites^{8,41}. D121A aSyn was chosen for further
136 investigation as it displayed a decreased aggregation rate using a thioflavin-T (ThT) based kinetic assay
137 compared to D115A, D119A and WT aSyn. However, there was no difference in the overall structure
138 as determined by fourier transform infrared spectroscopy (FTIR), which revealed disordered
139 structures for all these variants, as discussed in SI (Figure S4-6).

140 We first compared the conformation of monomeric D121A and pS129 aSyn to WT aSyn using ¹H-¹⁵N
141 heteronuclear single quantum correlation (HSQC) spectra in solution. In comparison to WT aSyn there
142 are chemical shift perturbations (CSPs) around the location of the D121A mutation, as expected, and
143 some additional small CSPs at regions aar 1-10 and 70-80 (Figure 2a, green) which may indicate some
144 disruption of long-range interactions in this mutant, as NMR measures an average of structural
145 ensembles. CSPs in pS129 aSyn were present around the phosphorylated S129 residue compared to
146 WT aSyn.

147 As CSPs of D121A and pS129 aSyn compared to WT aSyn were minimal aside the
148 mutation/phosphorylation sites, we next investigated whether addition of calcium could skew the
149 conformational ensemble of monomeric aSyn. Binding of calcium alters electrostatic interactions as it
150 neutralises the negative charge at the C-terminus of aSyn⁸. We observed significant CSPs at the C-
151 terminus for all three aSyn samples, as shown previously for WT aSyn (Figure 2b)³⁹. For D121A aSyn,
152 in addition to the main CSPs at the calcium binding area, we observe higher CSPs across the whole
153 sequence when compared with WT and pS129 aSyn, which is unexpected since a point mutation
154 usually only alters a very localised region of the sequence in a disordered protein⁴² (Figure 2b, green).
155 Furthermore, we observed no broadening of the NAC region when calcium was bound (Figure 2c),
156 such as present in WT aSyn³⁹, suggesting that interactions with the NAC region were altered in D121A

157 aSyn. Our data indicate that pS129 aSyn may also have altered long range interactions in comparison
158 to WT aSyn. Firstly, there appear to be more localised C-terminus CSPs upon calcium binding
159 compared to D121A and WT (Figure 2b, yellow). Residues involved in metal binding have previously
160 been shown to be altered upon phosphorylation⁴¹. Secondly, as observed for D121A aSyn, there was
161 no broadening of the NAC region when calcium was bound (Figure 2c). These alterations in CSPs upon
162 calcium binding suggest that long range interactions of pS129 and D121A aSyn are already altered
163 compared to WT aSyn which may have implications in terms of the aggregation propensity of these
164 mutants both in the absence and presence of calcium.



165

166 **Figure 2. 1H - ^{15}N spectra in the presence or absence of calcium of WT, D121A and pS129 aSyn indicate**
167 **conformational changes between the different variants.** (a) We compared chemical shift
168 perturbations in the amide backbone of 1H - ^{15}N D121A aSyn to WT aSyn (green) and pS129 aSyn to WT

169 aSyn (yellow) and observed CSPs around the location of the D to A mutation and the PO⁴ of S129 at
170 the C-terminus. Small CSPs were observed at residues 1-10 and 70-80 in D121A aSyn when compared
171 to WT aSyn. (b) Chemical shift perturbations were observed at the C-terminus upon addition of 4.2
172 mM calcium for all, WT (blue), D121A (green) and pS129 (yellow) aSyn. Higher CSPs are observed for
173 D121A compared to WT and pS129 aSyn. (c) 2D ¹H-¹⁵N HSQC NMR spectra of pS129 and D121A aSyn
174 in the absence (red) and in the presence of calcium (green). Major chemical shift perturbations in the
175 presence of calcium are located at the C terminus (arrows with assigned amino acid residues) in both
176 pS129 and D121A aSyn.

177 In order to determine whether the above structural changes we observed in the presence of calcium
178 were simply due to changes in the affinity for calcium of the different aSyn variants, we performed
179 calcium titrations experiments. We applied two different fitting algorithms to determine the
180 dissociation constant. Using a previously applied model⁴³, but this time using a fixed ligand (calcium)
181 number of 3 (which relates to the number of calcium ions bound as determined by MS with the same
182 aSyn to calcium ratio), we obtained a K_D of 95 (\pm 16) μ M, 91 (\pm 16) μ M and 69 (\pm 8) μ M for WT, pS129
183 and D121A aSyn, respectively. Using the Hill equation, which also takes into account the level of
184 cooperativity, we obtain a K_D of 670 (\pm 51) μ M, 670 (\pm 33) μ M and 460 (\pm 27) μ M for WT, pS129 and
185 D121A aSyn, respectively. For all fittings, we get an $n > 1$, indicating that calcium binds cooperatively
186 to aSyn (Figure S7).


187 We next performed ThT-based kinetic assays to investigate whether the above observed
188 conformational differences or calcium binding capacities of aSyn influenced the aggregation
189 propensity of the three aSyn variants. The results of the assay showed that although D121A and pS129
190 aSyn had different charges at the C-terminus, both had a lower aggregation propensity than WT aSyn,
191 particularly in the absence of calcium (Figure S8). The presence of calcium did increase the aggregation
192 rate of D121A and pS129 aSyn in comparison to aggregation rates without calcium, however not to
193 the same extent as the rate of WT aSyn. This was also reflected in the concentration of remaining
194 monomer determined by size-exclusion chromatography high-pressure liquid chromatography (SEC-
195 HPLC) (Figure S8 and S9). It thus appears that the affinity of aSyn to calcium does not influence
196 aggregation rate per se as the affinity of D121A aSyn for calcium is higher than of WT and pS129 aSyn.

197

198 **D121A and pS129 aSyn are less exposed at the N-terminus compared to WT aSyn upon calcium**
199 **addition**

200 We further investigated whether the perturbations observed by NMR led to shielding or exposure of
201 D121A and pS129 aSyn monomers using HDX-MS. This technique probes the submolecular structure
202 and dynamics of proteins by employing hydrogen-deuterium exchange, and thus permit the
203 identification of protein sequences that are more exposed to the solvent and/or less strongly
204 hydrogen-bonded (deprotected). Binary comparison of the deuterium uptake profile between WT and
205 D121A aSyn and WT and pS129 aSyn showed that both variants are not significantly different to WT
206 aSyn (Figure 3a and b).

207 We again used calcium to perturb the ensemble of conformations to compare alterations of long-
208 range interactions between the three aSyn variants. Binary comparison of the deuterium uptake
209 profile of monomeric WT aSyn revealed solvent protection at the C-terminus and significant
210 deprotection at the NAC and the N-terminus region of aSyn in the presence of calcium compared to
211 the absence of calcium (Figure 3c). This indicates that, when calcium is bound to aSyn, there is reduced
212 exposure to the solvent or increased hydrogen bonding at the C-terminus of aSyn, where calcium
213 binds, and deprotection of the N-terminus, as observed by CSPs using NMR. A similar behaviour was
214 also observed for D121A and pS129 aSyn as, upon calcium binding, solvent protection is observed at
215 the C-terminus and deprotection at the NAC region of aSyn (Figures 3d,e). However, while D121A aSyn
216 has a more solvent exposed N-terminus, pS129 aSyn displays little difference in protection levels at
217 the N-terminus. Despite both of these averaging structures being deprotected upon the addition of
218 calcium, they are still more protected/less exposed compared to WT aSyn in the calcium-bound state
219 (Figure 3c-e). Both NMR and HDX-MS indicate that D121A and pS129 aSyn have different ensembles
220 of conformations compared to WT aSyn. Upon perturbation of the conformational ensemble by
221 calcium binding, the degree of exposure of the N-terminus is much less pronounced in D121A and
222 pS129 aSyn than in WT aSyn. This correlates with the reduced aggregation propensity in the calcium-
223 bound state of D121A and pS129 aSyn, as determined by the ThT fluorescence kinetic assay.



224

225 **Figure 3. HDX-MS reveals different structural conformations in monomeric D121A and pS129**

226 **compared to WT aSyn.** Bars represent differences in deuterium uptake along the sequence of

227 differently compared aSyn variants (e.g. WT vs D121A aSyn) with the N-terminus labelled in blue, the

228 NAC region in yellow, and the C-terminus of aSyn in red. Negative values represent increased

229 deuterium uptake in the mutant (a,b) or in the calcium bound state (c-e), more solvent exposure, and

230 less hydrogen bonding. Peptides containing the mutation were not comparable to WT aSyn and were

231 removed from the data set, indicated by blank regions. Comparison of the deuterium uptake (in Dalton

232 -Da) between (a) WT and D121A aSyn and (b) WT and pS129 aSyn showed that both were not

233 significantly different to WT aSyn. (c) In the presence of calcium, WT aSyn becomes significantly more

234 deprotected (more solvent exposed/less hydrogen bonded) at the N-terminus and the NAC region,

235 and at the same time becomes solvent protected at the C-terminus. (d) D121A aSyn is significantly

236 more deprotected at the N-terminus and the NAC region upon calcium addition and solvent protected
237 at the C-terminus. (e) pS129 aSyn is deprotected at the NAC region upon calcium addition and solvent
238 protected at the C-terminus. The grey trace signifies the error (1 s.d.) of six replicates collected per
239 condition. Data acquired at each peptide were subjected to a Student's t-test with a p-value ≤ 0.05
240 and significant differences are presented by a *.

241


242 **Familial aSyn mutants display differences in aggregation propensity and N-terminus solvent** 243 **exposure compared to WT aSyn**

244 To further investigate whether differences in the sub-molecular structure are apparent in the familial
245 aSyn mutants A30P, E46K, A53T, A53E, H50Q, and G51D and whether this can influence aggregation
246 rates, we first studied their aggregation kinetics in the presence and absence of calcium using ThT-
247 based kinetic assays. Comparison of the fibrillisation rates of the familial mutants with WT aSyn in the
248 absence of calcium shows that the aSyn mutants E46K, A53T, and H50Q aggregate faster than WT
249 aSyn while the familial aSyn mutants A30P, A53E, and G51D aggregate more slowly than WT aSyn
250 (Figure S10). Upon the addition of calcium, WT aSyn nucleation and elongation is enhanced, as
251 previously shown³⁹, and for the fast aggregating aSyn mutants, A53T, E46K, and H50Q the aggregation
252 rate is also enhanced upon the addition of calcium, similarly to WT aSyn. However, the slow
253 aggregating aSyn mutants A30P, A53E, and G51D are either insensitive to calcium addition or
254 aggregate more slowly. In order to determine whether the difference in aggregation was due to
255 structural differences of the monomer, we again employed FTIR spectroscopy. The monomeric familial
256 aSyn mutants all had an increased beta-sheet content, particularly A30P, E46K and A53T aSyn which
257 were significantly different (Figure S11).

258

259 To gain more detailed and localised structural information than obtained by FTIR, we employed HDX-
260 MS. The familial aSyn mutants A53T and A53E were selected from the familial mutants' panel for this
261 analysis, as they displayed different aggregation behaviour, even though the point mutations were
262 localised on the same residue. Binary comparison of WT and A53T aSyn in the absence of calcium
263 showed that there was no significant difference in deuterium uptake between the two protein states
264 (Figure 4a), as observed for comparisons between WT and A53E aSyn (Figure 4b), and also A53T and
265 A53E aSyn in the absence of calcium (Figure 4c). Upon the addition of calcium, solvent protection is
266 observed at the C-terminus of A53T and A53E aSyn similar to WT and the other aSyn variants (see
267 D121A and pS129 aSyn), indicating that the protection at this region is primarily due to calcium
268 binding. At the same time, A53T aSyn is significantly deprotected at the N-terminus, at a similar level

269 to WT aSyn, indicating a breaking of hydrogen bonding or a local unfolding event (Figure 4d,e). In
270 contrast to the latter, for A53E aSyn (Figure 4f) no significant differences can be identified, neither at
271 the NAC region nor at the N-terminus, upon calcium binding. Thus, the extent to which structural
272 dynamics are perturbed in the N-terminal region in response to binding of calcium at the C-terminus
273 correlates with an increase in the aggregation propensity of aSyn and its variants.



274
275 **Figure 4. HDX-MS reveals different structural conformations of monomeric A53E compared to WT**
276 **and A53T aSyn.** Bars represent differences in deuterium uptake along the sequence of differently
277 compared aSyn variants with the N-terminus labelled in blue, the NAC region in yellow, and the C-
278 terminus in red. Negative values represent increased deuterium uptake in the mutant (a-c) or in the
279 calcium bound state (d-f), more solvent exposure, and less hydrogen bonding. Peptides containing the
280 mutation were not comparable to WT aSyn and were removed from the data set, indicated by blank


281 regions. Difference in deuterium uptake (Da) between (a) WT and A53T aSyn, (b) WT and A53E aSyn
282 and (c) A53T and A53E aSyn showed no significant differences throughout the sequence. In the
283 presence of calcium, as shown in Figure 2c, (d) WT aSyn becomes significantly deprotected at the N-
284 terminus and the NAC region, and more solvent protected at the C-terminus. (e) Similarly, A53T aSyn
285 is significantly deprotected at the N-terminus and the NAC region upon calcium addition, and at the
286 same time becomes solvent protected at the C-terminus. (f) A53E aSyn also becomes solvent
287 protected at the C-terminus upon calcium addition but no significant changes are observed at the NAC
288 region and most of the N-terminus. The grey trace signifies the error (1 s.d.) of six replicates collected
289 per condition. Data acquired were subjected to a Student's t-test with a p-value ≤ 0.05 and significant
290 differences are presented by a *.

291

292 **The distribution of aSyn conformations is altered upon calcium binding**

293 Techniques such as NMR and HDX-MS measure an ensemble of all conformations in the sample. Native
294 nano-ESI IM-MS can instead characterise heterogeneous structural ensembles, which permits us to
295 determine whether there is a difference in the distribution of conformations in the protein ensemble
296 between different aSyn variants. The ion mobility of a protein is measured inside the mass
297 spectrometer and determined by the number of collisions the protein ions have with gas molecules,
298 influencing the drift (or arrival) time which is a direct correlation to the rotationally averaged size and
299 shape of the particle. The larger the collision cross section (CCS), the more extended the conformation
300 of aSyn, and the lower the CCS, the more compact the conformation. In the gas-phase, WT aSyn was
301 found to have four main conformational distributions at the 8+ charge state (Figure 5a) which have
302 been observed previously⁴⁴⁻⁴⁶. A shoulder on the D peak of the protein profile in the arrival time
303 distribution (ATD) suggests that there is an additional weak conformation present (E) at this charge
304 state (Figure S12). As the charge state increases, the aSyn conformations become more extended due
305 to a higher coulombic repulsion (Figure S13). The familial mutations also display four main co-existing
306 conformational distributions, and no significant differences in overall compactness are observed
307 compared to WT aSyn (Figure 5a, Figure S12). The ATD containing the main four CCS values at 8+ was
308 subdivided into regions labelled A-D, with region E containing the least abundant and most compact
309 conformation. Analysis of the data by both intensity (Figure 5a) and calculation of the area under each
310 peak in the ATD, displayed as a percentage of the total population (Figure 5b) reveals no significant
311 differences in the distribution of the ensemble of conformations between WT and mutant aSyn. There
312 are however slight differences in the distribution of conformations between the different aSyn
313 variants (Figure 5, Table S1 and S2).

314 Upon addition of calcium, compacted conformations are favoured in all aSyn variants, particularly
315 conformation C, as indicated by more populated low CCS values (Figure 5a, +2Ca²⁺). Furthermore,
316 analysis of the mass spectra showed that there were no significant differences in the distribution and
317 maximum number of calcium ions bound to any of the aSyn variants, with, on average, two to three
318 Ca²⁺ ions bound at a 1:10 protein to calcium ratio (Figure S14, S15).



319

320 **Figure 4. Nano-ESI-IM-MS reveals differences in aSyn conformation equilibria and compactions**
321 **upon addition of calcium.** Heat maps of aSyn conformations detected for the 8+ charge state based
322 on intensity for (a) WT aSyn and the aSyn familial mutations, A30P, E46K, A53E, A53T, H50Q and G51D
323 in the absence (No Ca²⁺) and presence of calcium at a 1:20 protein to calcium ratio, representing a two
324 Ca²⁺ bound state (+2 Ca²⁺). Red represents the most populated CCS values by intensity. Upon addition
325 of calcium, a higher proportion of aSyn have a lower collisional cross section (CCS) value (seen in the
326 most populated region C), representing compaction. The area is separated into regions A, B, C, D, E at
327 the right of the heat maps to denote and quantify the population of different conformations. (b) The

328 conformational distributions of WT and mutant aSyn expressed as percentage were calculated from
329 the area under each section or peak in the ATD and are presented in the absence (Without Ca²⁺) and
330 presence of calcium (+2 Ca²⁺) and also in Tables S1, S2 including statistical analysis.

331

332 **Discussion**

333

334 As an intrinsically disordered protein, aSyn is constantly sampling a large conformational space and
335 exists as an ensemble of conformations. The distribution of these conformations is significantly
336 influenced by both changes in the sequence of the protein (e.g. mutations or PTMs) and the
337 surrounding environment. Some of these structural conformers are expected to follow different
338 aggregation pathways, possibly resulting in different fibril polymorphs and even leading to different
339 disease outcomes. By understanding how genetic and environmental factors, such as mutations, PTMs
340 and calcium, influence the dynamics of conformation and favour monomeric aggregation-prone
341 structures we may begin to understand the initiation of misfolding pathways leading to different
342 synucleinopathies, and subsequently how to disrupt them. However, here within lies the difficulty as
343 the conformations monomeric aSyn samples are similar in size, charge and structure and are thus hard
344 to detect using ensemble measurement techniques. Furthermore, it is difficult to discern differences
345 in overall conformations when comparing mutant to WT aSyn. In this study, we used the biologically
346 relevant ion, calcium, to perturb the conformational ensemble of aSyn structures and compared the
347 differences in CSPs, hydrogen bonding/solvent exposure and distribution of conformations between
348 aSyn and its mutants. In general, calcium has been shown to enhance the aggregation rate of aSyn
349 ^{39,47}, likely by a similar mechanism as low pH, whereby the reduction of the negative charge at the C-
350 terminus leads to C-terminal collapse, altered long-range electrostatic interactions and enhanced
351 hydrophobic interaction between the C-terminus and the NAC region which drives aggregation ^{22,48-}
352 ⁵¹. We observed mutant specific differences in long-range interactions, compaction and solvent
353 exposure compared to WT aSyn which will be discussed individually.

354

355 **Mutation and phosphorylation at the C-terminus alter long-range interactions**

356 We first investigated the role of charge and long range interactions at the C-terminus by comparing
357 two aSyn variants with reduced (D121A) and added (pS129) negative charge. We observed that both,
358 D121A and pS129 aSyn displayed reduced aggregation rates in comparison to WT aSyn, indicating that
359 increasing or decreasing charge by one residue at the C-terminus does not decrease or increase
360 aggregation rates, respectively, as may have been expected. Many studies investigating the effect of
361 charge on aSyn aggregation rates use C-terminus truncations which heavily disrupt and remove long-

362 range interactions. aSyn truncated at Y133 and D135 leads to increased aggregation rates, but
363 phosphorylation at S129 of these truncated aSyn reduces the aggregation rate, suggesting
364 phosphorylation at S129 does have an inhibitory effect on aggregation⁵². Furthermore, calcium
365 binding affinity does not correlate with aggregation rates, suggesting that altered residual monomeric
366 structure at specific regions and not calcium binding or alteration of single charges per se influences
367 aggregation rates. We observed only small differences in the conformational properties of the
368 monomeric aSyn, as revealed by changes in CSPs and solvent exposure for D121A or pS129 compared
369 to WT aSyn in the absence of calcium. This is likely due to the vast array of conformations sampled by
370 the protein leading to minimal structural changes using protein ensemble measurement techniques
371 such as NMR and HDX-MS. However, by perturbing the ensemble of conformations, as seen upon the
372 addition of calcium, we could observe differences in CSPs and deuterium uptake upon calcium binding.
373 pS129 aSyn has a different calcium-binding region and displays no broadening in the NAC region
374 compared to WT aSyn, while D121A has a higher degree of CSPs across the sequence, but also no NAC
375 region broadening, suggesting long-range interactions with the NAC region in both these mutants are
376 altered before calcium binds. Broadening in the NAC region has been observed for WT aSyn when
377 bound to calcium³⁹ and at low pH, suggesting enhanced interactions between calcium binding
378 region, namely the charge neutralised C-terminus, and the NAC region²². Regarding aSyn's propensity
379 to aggregate, we observe, using HDX-MS, that the N-terminus of pS129 aSyn is not solvent exposed
380 upon calcium binding, whereas for D121A aSyn, although the N-terminus is slightly exposed, is
381 significantly less exposed compared to WT aSyn upon calcium binding, correlating to the decreased
382 aggregation propensity of D121A and pS129 aSyn. Previous HDX-MS studies have suggested that the
383 N-terminus of aSyn may be involved in aggregation as there is heterogeneity in its solvent exposure
384 during aggregation which is also linked to fibril morphology, while the C-terminus remains completely
385 solvent exposed⁵³⁻⁵⁵. Here, we show that the extent of N-terminus (aar 1-60) and NAC region (aar 61-
386 95) exposure, based on the amount of deuterium exchange which is determined by ease of
387 accessibility, is correlated to the aggregation propensity of aSyn, where WT>D121A>pS129 in terms
388 of N-terminus exposure, but the opposite is observed for aggregation propensity. Importantly, we *only*
389 observe N-terminus exposure upon the disruption of long-range interactions with the C-terminus
390 upon calcium binding. The C-terminus thus greatly influences aggregation propensity, as it is
391 important in maintaining long range interactions and solubility of monomeric aSyn^{56,57}. Mutation of
392 proline⁵⁸, or glutamate⁵⁷ residues to alanine at the C-terminus increases aSyn aggregation propensity,
393 yet mutation of tyrosine²⁷ residues to alanine decreases aSyn aggregation propensity. This suggests
394 that mutations of specific residues alter specific long-range interactions which subsequently influence
395 the distributions of conformations within the dynamic ensemble and thus the aggregation propensity

396 of aSyn and its variants. Even phosphorylation of S129 compared to Y125 aSyn (only 4 aa apart) leads
397 to differences in aggregation rates, as pY125 does not influence the aggregation rate compared to WT
398 aSyn⁵⁹, neither the binding capacity of aSyn to nanobodies nor the alteration of metal binding sites,
399 indicating very site-specific functions and interactions are present at the C-terminus^{41,59}. Although
400 D121A aSyn is not a naturally occurring mutation, by comparing it to pS129, we can explore how
401 altering long-range interactions of monomeric aSyn at the C-terminus by mutation, PTM or addition
402 of divalent cations leads to altered interactions with the NAC region and different levels of solvent
403 exposure at the N-terminus. Mutations leading to altered long-range interactions lead to a favouring
404 of non-aggregation prone conformations in pS129 and D121 aSyn presented here, but under other
405 environmental conditions not tested here, a favouring of aggregation prone conformations may also
406 occur, and thus both sequence and environment are important in determining aSyn's aggregation
407 propensity.

408

409 **Familial aSyn mutants display different long-range interactions**

410 While all familial aSyn point mutations reside at the N-terminus, the putative calcium binding site is
411 at the C-terminus⁶⁰. Certainly, the presence of a familial aSyn mutation has been shown to alter
412 interactions between the mutation site and the C-terminus by NMR compared to WT aSyn, with
413 regional differences apparent for each aSyn mutant in physiological and mildly acidic conditions^{23,35}.
414 In the present study, we observe that the familial aSyn mutants have different aggregation kinetics in
415 response to calcium, which is understandable considering the mutation regions interact with the
416 calcium binding regions at the C-terminus. Using HDX-MS, we observe a difference in the level of
417 solvent protection at the N-terminus of A53T and A53E aSyn upon binding of calcium suggesting that
418 indeed different long-range interactions are present. A local unfolding event (deprotection) at the N-
419 terminus and the NAC region of WT and A53T aSyn correlates with their increased aggregation
420 propensity upon calcium addition. No such deprotection was observed for the aSyn mutant A53E,
421 whose aggregation kinetics were similar in the presence and absence of calcium. We expect that the
422 release of long-range contacts with the C-terminus leads to exposure of the N-terminus and the NAC
423 region, which is observed in WT and A53T aSyn, to be a major factor influencing aSyn aggregation
424 kinetics. Several experiments have shown the importance of the N-terminus in modulating aSyn
425 aggregation. The presence of repeating units, KTKE, across the N-terminus seems to have an important
426 role because addition, deletion, swapping and their spacing lead to differential aggregation rates^{61,62}.
427 Furthermore, cross linking G41C and V48C leads to inhibition of aggregation⁶³, and targeting proteins
428 that bind to aa 37-54 prevents aggregation^{64,65}. It must be noted that all the familial aSyn mutations

429 are also present at the N-terminus and several studies have shown the mutant aSyn have destabilised
430 monomeric structures and altered long-range interactions compared to WT aSyn^{66–70}. The altered
431 stability combined with a lower propensity to form an α -helix, as observed by FTIR, at the N-terminus
432 compared to WT aSyn, may skew the distribution of the conformational ensemble leading to
433 conformations with high propensity to form oligomers and fibrils^{67,68,71,72}. We observe increased N-
434 terminus solvent exposure for the ‘fast aggregating’ mutant A53T compared to the ‘slow aggregating’
435 mutant A53E. In another study, the ‘fast aggregating’ mutant, E46K, also displays an increased solvent
436 exposure across its sequence, and, in addition, N-terminus residues are involved in oligomerisation³⁵.
437 The fact that such differences in aSyn long-range contacts and an increase in N-terminus solvent
438 exposure can be identified as early as the monomer level, and correlate to the propensity to fibrillise
439 is important, and a step towards understanding early events in the misfolding pathway and how
440 structure and environmental factors may influence aggregation propensity of the monomer.

441

442 To gain insight into the mechanisms by which mutations associated with familial PD alter aggregation
443 kinetics of aSyn, we sought to determine whether there were differences in the distribution of
444 monomer conformations between the familial aSyn mutants and WT aSyn using native nano-ESI-IM-
445 MS. We observed the presence of more than one population of conformations of aSyn in the gas
446 phase, indicating that aSyn may also take on a multitude of different conformations in solution. Upon
447 calcium addition, the conformational ensemble shifted towards favouring compacted structures in all
448 aSyn mutants as the C-terminus collapses due to charge neutralisation upon binding to calcium, which
449 has also been previously observed when Mn^{2+} and Co^{2+} bind WT aSyn⁴⁴. Divalent cation binding is
450 specific to the C-terminus, leading to compaction of aSyn conformations, non-specific binding of
451 monovalent ions (e.g. K^+ , Na^+) leads to extended structures being favoured due to charge shielding of
452 the N- and C-termini (A.D. Stephens, et. al., in preparation). Of note, the CCS values most favoured in
453 the calcium-bound state in region C are also present in the non-calcium bound state, but to a lesser
454 extent, it is thus possible that calcium binding leads to a bias towards structures that are already
455 available to the monomer in the calcium-free state. The increase in aggregation propensity of WT aSyn
456 upon calcium binding cannot only be explained by charge neutralisation at the C-terminus as all
457 familial aSyn mutants should have responded in the same way to calcium which was not the case. It is
458 more likely that the difference in aggregation propensity is a result of perturbed long-range
459 interactions between the C-terminus, and thus the sequence and its interaction with the local
460 environment, which skew the population towards more aggregation prone structures. Multiple
461 conformations are likely present in each CCS value group, suggesting that nano-ESI-IM-MS today may

462 not have the resolution to determine differences in the ensemble of conformations between WT and
463 mutant aSyn.


464

465 **Conclusions**

466 As an IDP, aSyn samples many different conformations making it difficult to identify specific
467 aggregation prone conformations, particularly using ensemble measurement techniques. By
468 comparing the submolecular structure of calcium-bound aSyn variants, we instead sampled a skewed
469 population and inferred differences in structure and aggregation propensity as part of a response to
470 calcium binding at the monomer level. We attribute the increase in aggregation propensity upon
471 calcium binding to structural perturbation, as we observe no correlation in aSyn's aggregation
472 propensity to its affinity to calcium, the number of calcium ions bound or charge neutralisation at the
473 C-terminus. Instead, we observe different responses to calcium based on the presence of different
474 long-range interactions which are likely already altered in non-calcium bound forms of the familial
475 mutants and upon the addition of PO_4^- at S129 (Figure 5). Calcium binding leads to further disruption
476 of intramolecular interactions with the C-terminus leading to unfolding and solvent exposure of the
477 N-terminus.

478 The extent of N-terminus solvent exposure upon C-terminal binding of calcium correlates with the
479 aggregation propensity of aSyn; pS129, A53E, and to some extent D121A aSyn were less solvent
480 exposed at the N-terminus and had a reduced aggregation propensity compared to WT and A53T aSyn
481 which were more aggregation prone and more solvent exposed at the N-terminus and at the beginning
482 of the NAC region (Figure 5). It remains to be determined whether these different structures of
483 monomeric aSyn can be isolated or whether they have different toxicity in cells. This would be an
484 important step in rationalising the molecular mechanism of PD and other synucleinopathies, by
485 identifying which local environmental factors bias the monomeric population towards the most
486 disease-relevant conformers. Finally, targeting the most disease-relevant monomeric structures of
487 aSyn and to convert them into 'normal' functional structures could open up a new chapter in the
488 design of therapeutics against PD and other synucleinopathies.

489



490

491 **Figure 5. Cartoon representation of the effect of phosphorylation, mutation and calcium binding on**

492 **aSyn.** (a) aSyn is a dynamic ensemble of conformations in solution. Its solubility is maintained by long-

493 range interactions between the N-terminus (blue), NAC region (yellow) and the C-terminus (blue) of

494 aSyn. (b) Addition of a phosphate group to S129 (purple circle) or mutation (purple cross) alters the

495 long-range interactions and skews the dynamic ensemble to favour or disfavour aggregation prone

496 structures. (c) Addition of divalent cations such as calcium (green) leads to charge shielding, C-

497 terminus collapse and exposure of the N-terminus of aSyn. (d) Calcium binding to phosphorylated or

498 mutated aSyn leads to different perturbations of long-range interactions. Phosphorylation at S129

499 leads to a slightly different calcium binding region and to reduced solvent exposure of the N-terminus

500 compared to WT aSyn. The aSyn mutation A53T (mid blue with purple cross) leads to N-terminus

501 solvent exposure upon calcium binding at the C-terminus, similar to WT aSyn, however the aSyn

502 mutation A53E (light blue with purple cross) leads to less N-terminus solvent exposure upon calcium

503 binding.

504

505 **Methods**

506 **Purification of aSyn**

507 Human wild-type (WT) alpha-synuclein was expressed using plasmid pT7-7. ASyn mutations D115A,
508 D119A, D121A, A30P, E46K, A53T, A53E, H50Q and G51D were introduced using the QuikChange
509 Lighting Site-Directed Mutagenesis K (Agilent Technologies LDA UK Limited, UK) and confirmed by
510 sequencing (Source Bioscience, Nottingham, UK). The plasmids were heat shocked into Escherichia
511 coli One Shot® BL21 STAR™ (DE3) (Invitrogen, Thermo Fisher Scientific, Cheshire, UK) and purified as
512 previously described¹⁸. Briefly, expressed aSyn was purified using ion exchange chromatography (IEX)
513 on a HiPrep Q FF 16/10 anion exchange column (GE Healthcare, Uppsala, Sweden). aSyn was then
514 further purified on a HiPrep Phenyl FF 16/10 (High Sub) hydrophobic interaction chromatography (HIC)
515 column (GE Healthcare). aSyn was extensively dialysed against 20 mM Tris pH 7.2 and concentrated
516 using 10 k MWCO amicon centrifugal filtration devices (Merck KGaA, Darmstadt, Germany) and stored
517 at -80 °C until use. Before experiments 1 mL of aSyn was further purified using a Superdex 75 pg
518 10/300 GL size exclusion chromatography (SEC) column (GE Healthcare) to obtain monomeric protein.
519 Purification was performed on an ÄKTA Pure (GE Healthcare). Protein concentration was determined
520 by measuring the absorbance at 280 nm on a Nanovue spectrometer using the extinction coefficient
521 5960 M⁻¹cm⁻¹.

522 Protein purity was analysed using analytical reversed phase chromatography. Each purification batch
523 was analysed using a Discovery BIO Wide Pore C18 column, 15cm x 4.6mm, 5µm, column with a guard
524 cartridge (Supelco by Sigma-Aldrich) with a gradient of 95% to 5% H₂O + 0.1% trifluoroacetic acid (TFA)
525 and acetonitrile + 0.1% TFA at a flow-rate of 1 mL/min. The elution profile was monitored by UV
526 absorption at 220 nm and 280 nm on an Agilent 1260 Infinity HPLC system (Agilent Technologies LDA
527 UK Limited, UK) equipped with an autosampler and a diode-array detector (a representative
528 chromatograph is shown in Figure S1A). Protein purity fell between 89 - 96 %.

529 **Purification of aSyn for nuclear magnetic resonance experiments**

530 E. coli was grown in isotope-enriched M9 minimal medium containing 15N ammonium chloride, and
531 13C-glucose similar to our previous protocol⁷³. Briefly, to isolate expressed aSyn the cell pellets were
532 resuspended in lysis buffer (10mM Tris-HCl pH 8, 1mM EDTA and EDTA-free complete protease
533 inhibitor cocktail tablets (Roche, Basel, Switzerland), 0.2 mM phenylmethylsulfonyl fluoride (PMSF)
534 and Pepstatin A and lysed by sonication. The cell lysate was centrifuged at 22,000 g for 30 min to
535 remove cell debris and the supernatant was then heated for 20 min at 90 °C to precipitate the heat-
536 sensitive proteins and subsequently centrifuged at 22,000 g. Streptomycin sulfate (Sigma-Aldrich)

537 10mg/ml was added to the supernatant to precipitate DNA. The mixture was stirred for 15 min
538 followed by centrifugation at 22,000 x g, then repeated. Ammonium sulfate 360 mg/ml was added to
539 the supernatant precipitate the protein aSyn. The solution was stirred for 30 min and centrifuged again
540 at 22,000 x g. The resulting pellet was resuspended in 25mM Tris-HCl, pH 7.7 and dialysed overnight.
541 The protein was purified by IEX on a HiPrep Q FF anion exchange column (GE Healthcare) and then
542 further purified by SEC on a HiLoad 16/60 Superdex 75 prep grade column (GE Healthcare). All the
543 fractions containing the monomeric protein were pooled together and concentrated by using amicon
544 10 k MWCO centrifugal filtration devices (Merck).

545

546 **Purification of phosphorylated serine 129 aSyn**

547 WT α -syn $^{13}\text{C}/^{15}\text{N}$ -labelled (α -syn $^{13}\text{C}/^{15}\text{N}$) was expressed and purified as previously described ^{71,74}.
548 Briefly, *E.coli* BL21(DE3) cells were transfected with a pT7-7 plasmid containing WT aSyn and was
549 cultured in an isotopically supplemented minimal media according to a previously described protocol
550 ⁷¹, then aSyn $^{13}\text{C}/^{15}\text{N}$ was purified using an anion exchange chromatography followed by reversed-
551 phase HPLC (RP-HPLC) purification using a Proto 300 C4 column and a gradient from 30 to 60% B over
552 35 min at 15 ml/min, where solvent A was 0.1% TFA in water and solvent B was 0.1% TFA in
553 acetonitrile, the fractions containing the protein were pooled and lyophilized and the protein was
554 stored at -20°C. For the preparation of phosphorylated S129 α -syn $^{13}\text{C}/^{15}\text{N}$ (aSyn $^{13}\text{C}/^{15}\text{N}$ pS129), we
555 used a previously established protocol using PLK3 kinase to introduce selectively the phosphorylation
556 at S129 ⁷⁵. The WT aSyn $^{13}\text{C}/^{15}\text{N}$ was resuspended in the phosphorylation buffer (50 mM HEPES, 1 mM
557 MgCl_2 , 1 mM EGTA, 1 mM DTT) at a concentration of $\sim 150 \mu\text{M}$ and then 2 mM of ATP and 0.42 μg of
558 PLK3 kinase (Invitrogen) per 500 μg of protein were added. The enzymatic reaction was left at 30°C
559 overnight without shaking. Upon complete phosphorylation, as monitored by mass spectroscopy
560 (LC/MS), aSyn $^{13}\text{C}/^{15}\text{N}$ pS129 was purified from the reaction mixture by RP-HPLC using an Inertsil
561 WP300-C8 semiprep column. Finally, the fractions containing the protein of interest were pooled and
562 quality control of aSyn $^{13}\text{C}/^{15}\text{N}$ pS129 was performed using mass spectroscopy, UPLC, and SDS-PAGE,
563 the protein was 99.89% phosphorylated (Figure S1B-D).

564 **Solution nuclear magnetic resonance (NMR)**

565 In order to probe the structure and thermodynamics of calcium binding with aSyn WT, pS129 and
566 D121A at a residue specific level, we employed a series of ^1H - ^{15}N HSQC experiments using different
567 concentrations of Ca^{2+} (0.0 mM to 4.2 mM) and a fixed concentration of aSyn (200 μM). NMR
568 experiments were carried out at 10°C on a Bruker spectrometer operating at ^1H frequencies of 800
569 MHz equipped with triple resonance HCN cryo-probe. The ^1H - ^{15}N HSQC experiments were recorded

570 using a data matrix consisting of 2048 ($t_2, {}^1\text{H}$) \times 220 ($t_1, {}^{15}\text{N}$) complex points. Assignments of the
 571 resonances in ${}^1\text{H}$ - ${}^{15}\text{N}$ -HSQC spectra of aSyn were derived from our previous studies.
 572 The perturbation of the ${}^1\text{H}$ - ${}^{15}\text{N}$ HSQC resonances was analysed using a weighting function:

$$573 \quad \Delta\delta = \sqrt{\frac{1}{2}(\delta_H^2 + 0.15\delta_N^2)}$$

574 The titration enabled calculating the fraction of bound aSyn, χ_B , as a function of $[\text{Ca}^{2+}]$.

$$575 \quad \chi_B = \frac{\Delta\delta_{obs}}{\Delta\delta_{sat}}$$

576 Where the $\Delta\delta_{obs}$ is the chemical shift perturbation of the amide group of a residue of aSyn at a given
 577 $[\text{Ca}^{2+}]$ and $\Delta\delta_{sat}$ is the perturbation obtained with calcium saturation. χ_B values were obtained as a
 578 function of $[\text{Ca}^{2+}]$ for every residue of the protein for which resolved peaks in the ${}^1\text{H}$ - ${}^{15}\text{N}$ HSQC are
 579 available. A global χ_B was calculated by average the fractions corresponding to residues associated
 580 with major resonance perturbations in the presence of calcium.

581 In order to obtain the apparent dissociation constant we used two different models.

582 As first, we employed a model based on previous investigations³⁹:

$$583 \quad \alpha syn^U + (\text{Ca}^{2+})_L = \alpha syn^B (\text{Ca}^{2+})_L$$

584 Where αsyn^U and αsyn^B indicate free and calcium bound aSyn, L indicates the number of Ca^{2+}
 585 interacting with one aSyn molecule, and the overall concentration of aSyn in this equilibrium is given
 586 by

$$587 \quad [\alpha syn] = [\alpha syn^U] + [\alpha syn^B (\text{Ca}^{2+})_L]$$

588 the apparent dissociation constant in this model corresponds to:

$$589 \quad K_D = \frac{[\alpha syn^U][\text{Ca}^{2+}]_L}{[\alpha syn^B (\text{Ca}^{2+})_L]}$$

590 Which provides a formula for χ_B :

$$591 \quad \chi_B = \frac{[\alpha syn] + \left[\frac{\text{Ca}^{2+}}{L}\right] + K_D - \sqrt{\left([\alpha syn] + \left[\frac{\text{Ca}^{2+}}{L}\right] + K_D\right)^2 - \frac{4[\alpha syn][\text{Ca}^{2+}]}{L}}}{2[\alpha syn]}$$

592 When using this fitting model in the case of WT aSyn we obtained a K_D of 21 (± 5) μM and an L of 7.8
 593 (± 0.51)³⁹. Based on the present MS data, we here fixed the value of L to 3.

594 We then used a different model that accounts for the cooperativity of the binding. In particular, we
 595 used the Hill equation to fit our data:

$$596 \quad \chi_B = \frac{[\text{Ca}^{2+}]^n}{K_D + [\text{Ca}^{2+}]^n}$$

597 Where the Hill coefficient, n , describes the cooperativity of the binding. A n value higher than 1
 598 indicates a positive cooperativity for the binding.

599 **Hydrogen-deuterium exchange mass spectrometry (HDX-MS)**

600 Hydrogen exchange was performed using an HDX Manager (Waters, USA) equipped with a CTC PAL
601 sample handling robot (LEAP Technologies, USA). Samples of aSyn in protonated aqueous buffer (20
602 mM Tris, pH 7.2) were diluted 20-fold into deuterated buffer (20 mM Tris, pD 7.2) at 20 °C, initiating
603 hydrogen exchange. The same was performed for the calcium condition, in protonated and
604 deuterated buffers containing 1 mM CaCl₂ (20 mM Tris, pH 7.2, 1 mM CaCl₂, and 20 mM Tris, pD 7.2,
605 1 mM CaCl₂). The protein was incubated for 30 s in the deuterated buffer and six replicates were
606 collected per condition. Hydrogen exchange was arrested by mixing 1:1 with pre-chilled quench buffer
607 (100 mM Tris, 8 M Urea, pH 2.45 at 0 °C). The protein was then digested into peptides on a pepsin
608 column (Enzymate, Waters) and the peptides were separated on a C18 column (1x100 mm ACQUITY
609 UPLC BEH 1.7 µm, Waters) with a linear gradient of acetonitrile (3-40 %) supplemented with 0.2 %
610 formic acid. Peptides were analysed with a Synapt G2-Si mass spectrometer (Waters). The mass
611 spectrometer was calibrated with NaI calibrant in positive ion mode. A clean blank injection was ran
612 between samples to minimise carry-over. Peptide mapping of aSyn, where peptides were identified
613 by MS/MS fragmentation, was performed prior to the hydrogen exchange experiments and analysed
614 using ProteinLynx Global Server- PLGS (Waters). Peptide mapping of aSyn yielded coverage of 100%
615 of aSyn with a high degree of redundancy (5.32) (Figure S2). The data pertaining to deuterium uptake
616 (representative data presented in Figure S3) were analysed and visualised in DynamX 3.0 (Waters) and
617 GraphPad Prism (GraphPad Software, US). No correction was made for back-exchange.

618 **Nano electrospray ionisation ion mobility mass spectrometry (Nano ESI-IM-MS)**

619 A final concentration of 20 µM AS (WT or mutant) was obtained in 20 mM ammonium acetate (Sigma
620 Aldrich, St. Louis, MO, USA) pH 7 and measured as a control. CaCl₂ (Merck, Darmstadt, Germany) was
621 dissolved in deionised H₂O and added to the sample with a final concentration ranging between 200
622 µM and 400 µM. The samples were incubated for 10 minutes at room temperature before measuring.
623 Nano-ESI (ion mobility-) mass spectrometry (nano-ESI-IM-MS) measurements were performed on a
624 Synapt G2 HDMS (Waters, Manchester, U.K.) and analysed using Masslynx version 4.1 (Waters,
625 Manchester, U.K.). For infusion into the mass spectrometer, home-made gold-coated borosilicate
626 capillaries were used. The main instrumental settings were: capillary voltage 1.4-1.8 kV; sampling cone
627 25 V; extraction cone 1 V; trap CE 4 V; transfer CE 0 V; trap bias 40 V. Gas pressures used throughout
628 the instrument were: source 1.5-2.7 mbar; trap cell 2.3 x 10⁻² mbar; IM cell 3.0 mbar; transfer cell 2.5
629 x 10⁻² mbar.

630

631

632 **References**

- 633 (1) Shahmoradian, S. H.; Lewis, A. J.; Genoud, C.; Hench, J.; Moors, T. E.; Navarro, P. P.; Castañó-
634 Díez, D.; Schweighauser, G.; Graff-Meyer, A.; Goldie, K. N.; et al. Lewy Pathology in
635 Parkinson's Disease Consists of Crowded Organelles and Lipid Membranes. *Nat. Neurosci.*
636 **2019**, 22 (7), 1099–1109. <https://doi.org/10.1038/s41593-019-0423-2>.
- 637 (2) Mahul-Mellier, A.-L.; Altay, M. F.; Burtscher, J.; Maharjan, N.; Ait-Bouziad, N.; Chiki, A.; Vingill,
638 S.; Wade-Martins, R.; Holton, J.; Strand, C.; et al. The Making of a Lewy Body: The Role of α -
639 Synuclein Post-Fibrillization Modifications in Regulating the Formation and the Maturation of
640 Pathological Inclusions. *bioRxiv* **2018**, 500058. <https://doi.org/10.1101/500058>.
- 641 (3) Lautenschläger, J.; Kaminski, C. F.; Kaminski Schierle, G. S. α -Synuclein - Regulator of
642 Exocytosis, Endocytosis, or Both? *Trends Cell Biol.* **2017**.
643 <https://doi.org/10.1016/j.tcb.2017.02.002>.
- 644 (4) Logan, T.; Bendor, J.; Toupin, C.; Thorn, K.; Edwards, R. H. α -Synuclein Promotes Dilation of
645 the Exocytotic Fusion Pore. *Nat. Publ. Gr.* **2017**. <https://doi.org/10.1038/nn.4529>.
- 646 (5) Uversky, V. N.; Li, J.; Souillac, P.; Millett, I. S.; Doniach, S.; Jakes, R.; Goedert, M.; Fink, A. L.
647 Biophysical Properties of the Synucleins and Their Propensities to Fibrillate. *J. Biol. Chem.*
648 **2002**, 277 (14), 11970–11978. <https://doi.org/10.1074/jbc.M109541200>.
- 649 (6) Stephens, A. D.; Zacharopoulou, M.; Kaminski Schierle, G. S. The Cellular Environment Affects
650 Monomeric α -Synuclein Structure. *Trends Biochem. Sci.* **2019**, 44 (5), 453–466.
651 <https://doi.org/10.1016/j.tibs.2018.11.005>.
- 652 (7) Giasson, B. I.; Murray, I. V.; Trojanowski, J. Q.; Lee, V. M. A Hydrophobic Stretch of 12 Amino
653 Acid Residues in the Middle of Alpha-Synuclein Is Essential for Filament Assembly. *J. Biol.*
654 *Chem.* **2001**, 276 (4), 2380–2386. <https://doi.org/10.1074/jbc.M008919200>.
- 655 (8) Binolfi, A.; Rasia, R. M.; Bertocini, C. W.; Ceolin, M.; Zweckstetter, M.; Griesinger, C.; Jovin, T.
656 M.; Fernández, C. O. Interaction of α -Synuclein with Divalent Metal Ions Reveals Key
657 Differences: A Link between Structure, Binding Specificity and Fibrillation Enhancement. *J.*
658 *Am. Chem. Soc.* **2006**, 128 (30), 9893–9901. <https://doi.org/10.1021/ja0618649>.
- 659 (9) Polymeropoulos, M. H.; Lavedan, C.; Leroy, E.; Ide, S. E.; Dehejia, A.; Dutra, A.; Pike, B.; Root,
660 H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the α -Synuclein Gene Identified in Families
661 with Parkinson's Disease. *Science (80-.).* **1997**, 276 (5321), 2045–2047.
662 <https://doi.org/10.1126/science.276.5321.2045>.

- 663 (10) Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J. T.;
664 Schols, L.; Riess, O. Ala30Pro Mutation in the Gene Encoding α -Synuclein in Parkinson's
665 Disease. *Nat. Genet.* **1998**, *18* (2), 106–108. <https://doi.org/10.1038/ng0298-106>.
- 666 (11) Zarranz, J. J.; Alegre, J.; Gómez-Esteban, J. C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.;
667 Hoenicka, J.; Rodriguez, O.; Atarés, B.; et al. The New Mutation, E46K, of α -Synuclein Causes
668 Parkinson and Lewy Body Dementia. *Ann. Neurol.* **2004**, *55* (2), 164–173.
669 <https://doi.org/10.1002/ana.10795>.
- 670 (12) Proukakis, C.; Dudzik, C. G.; Brier, T.; MacKay, D. S.; Cooper, J. M.; Millhauser, G. L.; Houlden,
671 H.; Schapira, A. H. A Novel α -Synuclein Missense Mutation in Parkinson Disease. *Neurology*.
672 American Academy of Neurology March 12, 2013, pp 1062–1064.
673 <https://doi.org/10.1212/WNL.0b013e31828727ba>.
- 674 (13) Appel-Cresswell, S.; Vilarino-Guell, C.; Encarnacion, M.; Sherman, H.; Yu, I.; Shah, B.; Weir, D.;
675 Thompson, C.; Szu-Tu, C.; Trinh, J.; et al. Alpha-Synuclein p.H50Q, a Novel Pathogenic
676 Mutation for Parkinson's Disease. *Mov. Disord.* **2013**, *28* (6), 811–813.
677 <https://doi.org/10.1002/mds.25421>.
- 678 (14) Lesage, S.; Anheim, M.; Letournel, F.; Bousset, L.; Honoré, A.; Rozas, N.; Pieri, L.; Madiona, K.;
679 Dürr, A.; Melki, R.; et al. G51D α -Synuclein Mutation Causes a Novel Parkinsonian-Pyramidal
680 Syndrome. *Ann. Neurol.* **2013**, *73* (4), 459–471. <https://doi.org/10.1002/ana.23894>.
- 681 (15) Pasanen, P.; Myllykangas, L.; Siitonen, M.; Raunio, A.; Kaakkola, S.; Lyytinen, J.; Tienari, P. J.;
682 Pöyhönen, M.; Paetau, A. A Novel α -Synuclein Mutation A53E Associated with Atypical
683 Multiple System Atrophy and Parkinson's Disease-Type Pathology. *Neurobiol. Aging* **2014**, *35*
684 (9), 2180.e1-2180.e5. <https://doi.org/10.1016/j.neurobiolaging.2014.03.024>.
- 685 (16) Lill, C. M. Genetics of Parkinson's Disease. *Mol. Cell. Probes* **2016**, *30* (6), 386–396.
686 <https://doi.org/10.1016/j.mcp.2016.11.001>.
- 687 (17) Wu, K. P.; Baum, J. Detection of Transient Interchain Interactions in the Intrinsically
688 Disordered Protein α -Synuclein by NMR Paramagnetic Relaxation Enhancement. *J. Am. Chem.*
689 *Soc.* **2010**, *132* (16), 5546–5547. <https://doi.org/10.1021/ja9105495>.
- 690 (18) Stephens, A.; Nespovitaya, N.; Zacharopoulou, M.; Kaminski, F.; Phillips, J. J.; Schierle, G. S. K.
691 Different Structural Conformers of Monomeric Alpha- Synuclein Identified after Lyophilising
692 and Freezing. *Anal. Chem.* **2018**, *acs.analchem.8b01264*.
693 <https://doi.org/10.1021/acs.analchem.8b01264>.

- 694 (19) Dedmon, M. M.; Lindorff-Larsen, K.; Christodoulou, J.; Vendruscolo, M.; Dobson, C. M.
695 Mapping Long-Range Interactions in α -Synuclein Using Spin-Label NMR and Ensemble
696 Molecular Dynamics Simulations. *J. Am. Chem. Soc.* **2005**, *127* (2), 476–477.
697 <https://doi.org/10.1021/ja044834j>.
- 698 (20) Zhou, W.; Long, C.; Reaney, S. H.; Di Monte, D. A.; Fink, A. L.; Uversky, V. N. Methionine
699 Oxidation Stabilizes Non-Toxic Oligomers of α -Synuclein through Strengthening the Auto-
700 Inhibitory Intra-Molecular Long-Range Interactions. *Biochim. Biophys. Acta - Mol. Basis Dis.*
701 **2010**, *1802* (3), 322–330. <https://doi.org/10.1016/j.bbadis.2009.12.004>.
- 702 (21) Esteban-Martín, S.; Silvestre-Ryan, J.; Bertoncini, C. W.; Salvatella, X. Identification of Fibril-
703 like Tertiary Contacts in Soluble Monomeric α -Synuclein. *Biophys. J.* **2013**, *105* (5), 1192–
704 1198. <https://doi.org/10.1016/j.bpj.2013.07.044>.
- 705 (22) McClendon, S.; Rospigliosi, C. C.; Eliezer, D. Charge Neutralization and Collapse of the C-
706 Terminal Tail of Alpha-Synuclein at Low PH. *Protein Sci.* **2009**, *18* (7), 1531–1540.
707 <https://doi.org/10.1002/pro.149>.
- 708 (23) Ranjan, P.; Kumar, A. Perturbation in Long-Range Contacts Modulates the Kinetics of Amyloid
709 Formation in α -Synuclein Familial Mutants. *ACS Chem. Neurosci.* **2017**, *8* (10), 2235–2246.
710 <https://doi.org/10.1021/acchemneuro.7b00149>.
- 711 (24) Sung, Y.; Eliezer, D. Residual Structure, Backbone Dynamics, and Interactions within the
712 Synuclein Family. *J. Mol. Biol.* **2007**, *372* (3), 689–707.
713 <https://doi.org/10.1016/J.JMB.2007.07.008>.
- 714 (25) Bertoncini, C. W.; Jung, Y.-S.; Fernandez, C. O.; Hoyer, W.; Griesinger, C.; Jovin, T. M.;
715 Zweckstetter, M. From The Cover: Release of Long-Range Tertiary Interactions Potentiates
716 Aggregation of Natively Unstructured α -Synuclein. *Proc. Natl. Acad. Sci.* **2005**, *102* (5), 1430–
717 1435. <https://doi.org/10.1073/pnas.0407146102>.
- 718 (26) Afitska, K.; Fucikova, A.; Shvadchak, V. V.; Yushchenko, D. A. Modification of C Terminus
719 Provides New Insights into the Mechanism of α -Synuclein Aggregation. *Biophys. J.* **2017**, *113*
720 (10), 2182–2191. <https://doi.org/10.1016/j.bpj.2017.08.027>.
- 721 (27) Ulrih, N. P.; Barry, C. H.; Fink, A. L. Impact of Tyr to Ala Mutations on α -Synuclein Fibrillation
722 and Structural Properties. *Biochim. Biophys. Acta - Mol. Basis Dis.* **2008**, *1782* (10), 581–585.
723 <https://doi.org/10.1016/j.bbadis.2008.07.004>.
- 724 (28) Landeck, N.; Strathearn, K. E.; Ysselstein, D.; Buck, K.; Hulleman, J. D.; Hindupur, J.; Griggs, A.

- 725 M.; Padalkar, S.; Stanciu, A.; Kirik, D.; et al. Two C-Terminal Sequence Variations Determine
726 Differential Neurotoxicity between Human and Mouse α -Synuclein Natalie Landeck, 1,¶
727 Katherine E. Strathearn, 2, ¶, *bioRxiv* **2019**, 700377. <https://doi.org/10.1101/700377>.
- 728 (29) Roeters, S. J.; Iyer, A.; Pletikapić, G.; Kogan, V.; Subramaniam, V.; Woutersen, S. Evidence for
729 Intramolecular Antiparallel Beta-Sheet Structure in Alpha-Synuclein Fibrils from a
730 Combination of Two-Dimensional Infrared Spectroscopy and Atomic Force Microscopy. *Sci.*
731 *Rep.* **2017**, 7, 41051. <https://doi.org/10.1038/srep41051>.
- 732 (30) Anderson, J. P.; Walker, D. E.; Goldstein, J. M.; de Laat, R.; Banducci, K.; Caccavello, R. J.;
733 Barbour, R.; Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 Is the Dominant
734 Pathological Modification of Alpha-Synuclein in Familial and Sporadic Lewy Body Disease. *J.*
735 *Biol. Chem.* **2006**, 281 (40), 29739–29752. <https://doi.org/10.1074/jbc.M600933200>.
- 736 (31) Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M. S.; Shen,
737 J.; Takio, K.; Iwatsubo, T. A-Synuclein Is Phosphorylated in Synucleinopathy Lesions. *Nat. Cell*
738 *Biol.* **2002**, 4 (2), 160–164. <https://doi.org/10.1038/ncb748>.
- 739 (32) Samuel, F.; Flavin, W. P.; Iqbal, S.; Pacelli, C.; Renganathan, S. D. S.; Trudeau, L. E.; Campbell,
740 E. M.; Fraser, P. E.; Tandon, A. Effects of Serine 129 Phosphorylation on α -Synuclein
741 Aggregation, Membrane Association, and Internalization. *J. Biol. Chem.* **2016**, 291 (9), 4374–
742 4385. <https://doi.org/10.1074/jbc.M115.705095>.
- 743 (33) Paleologou, K. E.; Schmid, A. W.; Rospigliosi, C. C.; Kim, H. Y.; Lamberto, G. R.; Fredenburg, R.
744 A.; Lansbury, P. T.; Fernandez, C. O.; Eliezer, D.; Zweckstetter, M.; et al. Phosphorylation at
745 Ser-129 but Not the Phosphomimics S129E/D Inhibits the Fibrillation of α -Synuclein. *J. Biol.*
746 *Chem.* **2008**, 283 (24), 16895–16905. <https://doi.org/10.1074/jbc.M800747200>.
- 747 (34) Bertocini, C. W.; Fernandez, C. O.; Griesinger, C.; Jovin, T. M.; Zweckstetter, M. Familial
748 Mutants of α -Synuclein with Increased Neurotoxicity Have a Destabilized Conformation. *J.*
749 *Biol. Chem.* **2005**, 280 (35), 30649–30652. <https://doi.org/10.1074/jbc.C500288200>.
- 750 (35) Bhattacharyya, D.; Kumar, R.; Mehra, S.; Ghosh, A.; Maji, S. K.; Bhunia, A. Multitude NMR
751 Studies of α -Synuclein Familial Mutants: Probing Their Differential Aggregation Propensities.
752 *Chem. Commun.* **2018**, 54 (29), 3605–3608. <https://doi.org/10.1039/c7cc09597j>.
- 753 (36) Flagmeier, P.; Meisl, G.; Vendruscolo, M.; Knowles, T. P. J.; Dobson, C. M.; Buell, A. K.;
754 Galvagnion, C. Mutations Associated with Familial Parkinson's Disease Alter the Initiation and
755 Amplification Steps of α -Synuclein Aggregation. *Proc. Natl. Acad. Sci.* **2016**, 113 (37), 10328–

- 756 10333. <https://doi.org/10.1073/pnas.1604645113>.
- 757 (37) Wise-Scira, O.; Dunn, A.; Aloglu, A. K.; Sakallioğlu, I. T.; Coskuner, O. Structures of the E46K
758 Mutant-Type α -Synuclein Protein and Impact of E46K Mutation on the Structures of the Wild-
759 Type α -Synuclein Protein. *ACS Chem. Neurosci.* **2013**, *4* (3), 498–508.
760 <https://doi.org/10.1021/cn3002027>.
- 761 (38) Santner, A.; Uversky, V. N. Metalloproteomics and Metal Toxicology of α -Synuclein.
762 *Metallomics* **2010**, *2* (6), 378–392. <https://doi.org/10.1039/b926659c>.
- 763 (39) Lautenschläger, J.; Stephens, A. D.; Fusco, G.; Ströhl, F.; Curry, N.; Zacharopoulou, M.; Michel,
764 C. H.; Laine, R.; Nespovitaya, N.; Fantham, M.; et al. C-Terminal Calcium Binding of α -
765 Synuclein Modulates Synaptic Vesicle Interaction. *Nat. Commun.* **2018**, *9* (1), 712.
766 <https://doi.org/10.1038/s41467-018-03111-4>.
- 767 (40) Surmeier, D. J.; Guzman, J. N.; Sanchez-Padilla, J. Calcium, Cellular Aging, and Selective
768 Neuronal Vulnerability in Parkinson's Disease. *Cell Calcium* **2010**, *47* (2), 175–182.
769 <https://doi.org/10.1016/J.CECA.2009.12.003>.
- 770 (41) Lu, Y.; Prudent, M.; Fauvet, B.; Lashuel, H. A.; Girault, H. H. Phosphorylation of α -Synuclein at
771 Y125 and S129 Alters Its Metal Binding Properties: Implications for Understanding the Role of
772 α -Synuclein in the Pathogenesis of Parkinson's Disease and Related Disorders. *ACS Chem.*
773 *Neurosci.* **2011**, *2* (11), 667–675. <https://doi.org/10.1021/cn200074d>.
- 774 (42) Ghosh, D.; Sahay, S.; Ranjan, P.; Salot, S.; Mohite, G. M.; Singh, P. K.; Dwivedi, S.; Carvalho, E.;
775 Banerjee, R.; Kumar, A.; et al. The Newly Discovered Parkinsons Disease Associated Finnish
776 Mutation (A53E) Attenuates α -Synuclein Aggregation and Membrane Binding. *Biochemistry*
777 **2014**, *53* (41), 6419–6421. <https://doi.org/10.1021/bi5010365>.
- 778 (43) Galvagnion, C.; Buell, A. K.; Meisl, G.; Michaels, T. C. T.; Vendruscolo, M.; Knowles, T. P. J.;
779 Dobson, C. M. Lipid Vesicles Trigger α -Synuclein Aggregation by Stimulating Primary
780 Nucleation. *Nat. Chem. Biol.* **2015**, *11* (3), 229–234. <https://doi.org/10.1038/nchembio.1750>.
- 781 (44) Wongkongkathep, P.; Han, J. Y.; Choi, T. S.; Yin, S.; Kim, H. I.; Loo, J. A. Native Top-Down Mass
782 Spectrometry and Ion Mobility MS for Characterizing the Cobalt and Manganese Metal
783 Binding of α -Synuclein Protein. *J. Am. Soc. Mass Spectrom.* **2018**, *29* (9), 1870–1880.
784 <https://doi.org/10.1007/s13361-018-2002-2>.
- 785 (45) Konijnenberg, A.; Ranica, S.; Narkiewicz, J.; Legname, G.; Grandori, R.; Sobott, F.; Natalello, A.
786 Opposite Structural Effects of Epigallocatechin-3-Gallate and Dopamine Binding to α -

- 787 Synuclein. *Anal. Chem.* **2016**, *88* (17), 8468–8475.
788 <https://doi.org/10.1021/acs.analchem.6b00731>.
- 789 (46) Brodie, N. I.; Popov, K. I.; Petrotchenko, E. V.; Dokholyan, N. V.; Borchers, C. H.
790 Conformational Ensemble of Native α -Synuclein in Solution as Determined by Short-Distance
791 Crosslinking Constraint-Guided Discrete Molecular Dynamics Simulations. *PLoS Comput. Biol.*
792 **2019**, *15* (3). <https://doi.org/10.1371/journal.pcbi.1006859>.
- 793 (47) Han, J. Y.; Choi, T. S.; Kim, H. I. Molecular Role of Ca²⁺ and Hard Divalent Metal Cations on
794 Accelerated Fibrillation and Interfibrillar Aggregation of α -Synuclein. *Sci. Rep.* **2018**, *8* (1),
795 1895. <https://doi.org/10.1038/s41598-018-20320-5>.
- 796 (48) Uversky, V. N.; Li, J.; Fink, A. L. Evidence for a Partially Folded Intermediate in α -Synuclein
797 Fibril Formation. *J. Biol. Chem.* **2001**, *276* (14), 10737–10744.
798 <https://doi.org/10.1074/jbc.M010907200>.
- 799 (49) Bernstein, S. L.; Liu, D.; Wyttenbach, T.; Bowers, M. T.; Lee, J. C.; Gray, H. B.; Winkler, J. R. α -
800 Synuclein: Stable Compact and Extended Monomeric Structures and PH Dependence of
801 Dimer Formation. *J. Am. Soc. Mass Spectrom.* **2004**, *15* (10), 1435–1443.
802 <https://doi.org/10.1016/J.JASMS.2004.08.003>.
- 803 (50) Frimpong, A. K.; Abzalimov, R. R.; Uversky, V. N.; Kaltashov, I. A. Characterization of
804 Intrinsically Disordered Proteins with Electrospray Ionization Mass Spectrometry:
805 Conformational Heterogeneity of α -Synuclein. *Proteins Struct. Funct. Bioinforma.* **2010**, *78* (3),
806 714–722. <https://doi.org/10.1002/prot.22604>.
- 807 (51) Wu, K.-P.; Weinstock, D. S.; Narayanan, C.; Levy, R. M.; Baum, J. Structural Reorganization of
808 α -Synuclein at Low PH Observed by NMR and REMD Simulations. *J. Mol. Biol.* **2009**, *391* (4),
809 784–796. <https://doi.org/10.1016/j.jmb.2009.06.063>.
- 810 (52) Levitan, K.; Chereau, D.; Cohen, S. I. A. A.; Knowles, T. P. J. J.; Dobson, C. M.; Fink, A. L.;
811 Anderson, J. P.; Goldstein, J. M.; Millhauser, G. L. Conserved C-Terminal Charge Exerts a
812 Profound Influence on the Aggregation Rate of α -Synuclein. *J. Mol. Biol.* **2011**, *411* (2), 329–
813 333.
- 814 (53) Illes-Toth, E.; Rempel, D. L.; Gross, M. L. Pulsed Hydrogen-Deuterium Exchange Illuminates
815 the Aggregation Kinetics of α -Synuclein, the Causative Agent for Parkinson's Disease. *ACS*
816 *Chem. Neurosci.* **2018**, *9* (6), 1469–1476. <https://doi.org/10.1021/acscemneuro.8b00052>.
- 817 (54) Del Mar, C.; Greenbaum, E. A.; Mayne, L.; Englander, S. W.; Woods, V. L. Structure and

- 818 Properties of Alpha-Synuclein and Other Amyloids Determined at the Amino Acid Level. *Proc.*
819 *Natl. Acad. Sci. U. S. A.* **2005**, *102* (43), 15477–15482.
820 <https://doi.org/10.1073/pnas.0507405102>.
- 821 (55) Kumar, H.; Singh, J.; Kumari, P.; Udgaonkar, J. B. Modulation of the Extent of Structural
822 Heterogeneity in α -Synuclein Fibrils by the Small Molecule Thioflavin T. *J. Biol. Chem.* **2017**,
823 *292* (41), 16891–16903. <https://doi.org/10.1074/jbc.M117.795617>.
- 824 (56) Bertoncini, C. W.; Jung, Y.-S.; Fernandez, C. O.; Hoyer, W.; Griesinger, C.; Jovin, T. M.;
825 Zweckstetter, M. Release of Long-Range Tertiary Interactions Potentiates Aggregation of
826 Natively Unstructured α -Synuclein. *Proc. Natl. Acad. Sci.* **2005**, *102* (5), 1430–1435.
827 <https://doi.org/10.1073/pnas.0407146102>.
- 828 (57) Murray, I. V. J.; Giasson, B. I.; Quinn, S. M.; Koppaka, V.; Axelsen, P. H.; Ischiropoulos, H.;
829 Trojanowski, J. Q.; Lee, V. M. Y. Role of α -Synuclein Carboxy-Terminus on Fibril Formation in
830 Vitro. *Biochemistry* **2003**, *42* (28), 8530–8540. <https://doi.org/10.1021/bi027363r>.
- 831 (58) Meuvlis, J.; Gerard, M.; Desender, L.; Baekelandt, V.; Engelborghs, Y. The Conformation and
832 the Aggregation Kinetics of α -Synuclein Depend on the Proline Residues in Its C-Terminal
833 Region. *Biochemistry* **2010**, *49* (43), 9345–9352. <https://doi.org/10.1021/bi1010927>.
- 834 (59) El Turk, F.; De Genst, E.; Guillems, T.; Fauvet, B.; Hejjaoui, M.; Di Trani, J.; Chiki, A.;
835 Mittermaier, A.; Vendruscolo, M.; Lashuel, H. A.; et al. Exploring the Role of Post-
836 Translational Modifications in Regulating α -Synuclein Interactions by Studying the Effects of
837 Phosphorylation on Nanobody Binding. *Protein Sci.* **2018**, *27* (7), 1262–1274.
838 <https://doi.org/10.1002/pro.3412>.
- 839 (60) Nielsen, M. S.; Vorum, H.; Lindersson, E.; Jensen, P. H. Ca²⁺ Binding to α -Synuclein Regulates
840 Ligand Binding and Oligomerization. *J. Biol. Chem.* **2001**, *276* (25), 22680–22684.
841 <https://doi.org/10.1074/jbc.M101181200>.
- 842 (61) Kessler, J. C.; Rochet, J. C.; Lansbury, P. T. The N-Terminal Repeat Domain of α -Synuclein
843 Inhibits β -Sheet and Amyloid Fibril Formation. *Biochemistry* **2003**, *42* (3), 672–678.
844 <https://doi.org/10.1021/bi020429y>.
- 845 (62) Shvadchak, V. V.; Subramaniam, V. A Four-Amino Acid Linker between Repeats in the α -
846 Synuclein Sequence Is Important for Fibril Formation. *Biochemistry* **2014**, *53* (2), 279–281.
847 <https://doi.org/10.1021/bi401427t>.
- 848 (63) Shaykhalishahi, H.; Gauhar, A.; Wördehoff, M. M.; Grüning, C. S. R.; Klein, A. N.; Bannach, O.;

- 849 Stoldt, M.; Willbold, D.; Härd, T.; Hoyer, W. Contact between the B1 and B2 Segments of α -
850 Synuclein That Inhibits Amyloid Formation. *Angew. Chemie Int. Ed.* **2015**, *54* (30), 8837–8840.
851 <https://doi.org/10.1002/anie.201503018>.
- 852 (64) Mirecka, E. A.; Shaykhalishahi, H.; Gauhar, A.; Akgül, Ş.; Lecher, J.; Willbold, D.; Stoldt, M.;
853 Hoyer, W. Sequestration of a β -Hairpin for Control of α -Synuclein Aggregation. *Angew.*
854 *Chemie Int. Ed.* **2014**, *53* (16), 4227–4230. <https://doi.org/10.1002/anie.201309001>.
- 855 (65) Agerschou, E. D.; Flagmeier, P.; Saridaki, T.; Galvagnion, C.; Komnig, D.; Heid, L.; Prasad, V.;
856 Shaykhalishahi, H.; Willbold, D.; Dobson, C. M.; et al. An Engineered Monomer Binding-
857 Protein for α -Synuclein Efficiently Inhibits the Proliferation of Amyloid Fibrils. *Elife* **2019**, *8*.
858 <https://doi.org/10.7554/eLife.46112>.
- 859 (66) Krasnoslobodtsev, A. V.; Volkov, I. L.; Asiago, J. M.; Hindupur, J.; Rochet, J. C.; Lyubchenko, Y.
860 L. α -Synuclein Misfolding Assessed with Single Molecule AFM Force Spectroscopy: Effect of
861 Pathogenic Mutations. *Biochemistry* **2013**, *52* (42), 7377–7386.
862 <https://doi.org/10.1021/bi401037z>.
- 863 (67) Brucale, M.; Sandal, M.; Di Maio, S.; Rampioni, A.; Tessari, I.; Tosatto, L.; Bisaglia, M.;
864 Bubacco, L.; Samori, B. Pathogenic Mutations Shift the Equilibria of α -Synuclein Single
865 Molecules towards Structured Conformers. *ChemBioChem* **2009**, *10* (1), 176–183.
866 <https://doi.org/10.1002/cbic.200800581>.
- 867 (68) Wise-Scira, O.; Aloglu, A. K.; Dunn, A.; Sakallioglu, I. T.; Coskuner, O. Structures and Free
868 Energy Landscapes of the Wild-Type and A30P Mutant-Type α -Synuclein Proteins with
869 Dynamics. *ACS Chem. Neurosci.* **2013**, *4* (3), 486–497. <https://doi.org/10.1021/cn300198q>.
- 870 (69) Bertoncini, C. W.; Fernandez, C. O.; Griesinger, C.; Jovin, T. M.; Zweckstetter, M. Familial
871 Mutants of α -Synuclein with Increased Neurotoxicity Have a Destabilized Conformation. *J.*
872 *Biol. Chem.* **2005**, *280* (35), 30649–30652. <https://doi.org/10.1074/jbc.C500288200>.
- 873 (70) Bussell, R.; Eliezer, D. Residual Structure and Dynamics in Parkinson’s Disease-Associated
874 Mutants of α -Synuclein. *J. Biol. Chem.* **2001**, *276* (49), 45996–46003.
875 <https://doi.org/10.1074/jbc.M106777200>.
- 876 (71) Eliezer, D.; Kutluay, E.; Bussell, R.; Browne, G. Conformational Properties of α -Synuclein in Its
877 Free and Lipid-Associated States. *J. Mol. Biol.* **2001**, *307* (4), 1061–1073.
878 <https://doi.org/10.1006/JMBI.2001.4538>.
- 879 (72) Ferreon, A. C. M.; Gambin, Y.; Lemke, E. a; Deniz, A. a. Interplay of Alpha-Synuclein Binding

880 and Conformational Switching Probed by Single-Molecule Fluorescence. *Proc. Natl. Acad. Sci.*
881 *U. S. A.* **2009**, *106* (14), 5645–5650. <https://doi.org/10.1073/pnas.0809232106>.

882 (73) Fusco, G.; Pape, T.; Stephens, A. D.; Mahou, P.; Costa, A. R.; Kaminski, C. F.; Kaminski Schierle,
883 G. S.; Vendruscolo, M.; Veglia, G.; Dobson, C. M.; et al. Structural Basis of Synaptic Vesicle
884 Assembly Promoted by α -Synuclein. *Nat. Commun.* **2016**, *7*, 12563.
885 <https://doi.org/10.1038/ncomms12563>.

886 (74) Fauvet, B.; Fares, M. B.; Samuel, F.; Dikiy, I.; Tandon, A.; Eliezer, D.; Lashuel, H. A.
887 Characterization of Semisynthetic and Naturally N α - Acetylated α -Synuclein in Vitro and in
888 Intact Cells: Implications for Aggregation and Cellular Properties of α -Synuclein. *J. Biol. Chem.*
889 **2012**, *287* (34), 28243–28262. <https://doi.org/10.1074/jbc.M112.383711>.

890 (75) Fauvet, B.; Lashuel, H. A. Semisynthesis and Enzymatic Preparation of Post-Translationally
891 Modified α -Synuclein. In *Methods in Molecular Biology*; Humana Press, New York, NY, 2015;
892 Vol. 1345, pp 3–20. https://doi.org/10.1007/978-1-4939-2978-8_1.

893

894

895

896

897

898

899

900

901

902

903

904

905

906

Extent of N-terminus exposure by altered long-range interactions of monomeric alpha-synuclein determines its aggregation propensity

Supplementary Data

Contents

Figure S1. Analysis of aSyn WT and aSyn ¹³ C/ ¹⁵ N pS129 purity and percentage phosphorylation.	2
Figure S2. Peptide coverage map of aSyn in HDX-MS.	3
Figure S3. Deuterium uptake plots, measured in Dalton (Da), for representative peptides containing aar 4-17 (N-terminus) and aar 125-132 (C-terminus) of WT aSyn in the presence (red) and absence (blue) of calcium.....	4
Figure S4. ThT-based aggregation assay reveals that D121A aSyn does not aggregate to the same extent as WT, D115A and D119A upon incubation with calcium.	6
Figure S5. AFM reveals D121A aSyn forms mostly oligomeric structures, while WT, D115A and D119A aSyn form fibrillary structures upon incubation.	7
Figure S6. FTIR spectra and secondary structure analysis of WT and D to A mutant aSyn reveal no structural differences between the variants.	9
Figure S7. Dissociation constants of WT, pS129 and D121A aSyn and calcium reveal no significant differences between the different variants compared to WT aSyn and cooperative binding of calcium to aSyn.....	10
Figure S8. ThT-based aggregation assay reveals that D121A aSyn and pS129 aSyn do not aggregate as fast as WT aSyn.	10
Figure S9. Representative chromatograph of the remaining aSyn monomer concentration as determined at the end of the ThT-based assay and analysed by size exclusion chromatography.	12
Figure S10. ThT-based aggregation assay reveals that the aSyn familial mutants display different aggregation behaviour upon the addition of calcium.....	13
Figure S11. FTIR spectra and secondary structure analysis of monomeric WT aSyn and aSyn familial mutants reveal structural differences between the aSyn variants.....	15
Figure S12. Arrival time distribution (ATD) for aSyn conformations.	16
Figure S13. CCS values of aSyn WT and familial mutants show multiple coexisting conformations and extensions at higher charge states.	17
Table S1. Average percentage of the distribution of conformations of WT aSyn and mutants determined by nano-ESI-IM-MS in the absence calcium shows small changes in percentage distribution of conformations between the aSyn and its variants.	18
Table S2. Average percentage of the distribution of conformations of WT and aSyn mutants determined by nano-ESI-IM-MS in the presence of calcium shows significant differences upon the addition of calcium to aSyn and its variants.	18
Figure S14. Analysis of number of Ca ²⁺ ions bound to different aSyn mutants at different protein to ratios reveals no significant differences between the different aSyn variants.	19
Figure S15. Native nano ESI-MS spectra of WT aSyn with increasing concentrations of calcium shows that up to 11 calcium ions can be bound to aSyn at a 1:250 protein to calcium ratio.....	20




Figure S1. Analysis of WT and $^{13}\text{C}/^{15}\text{N}$ pS129 aSyn purity and percentage phosphorylation. (A) Representative chromatograph of WT aSyn analysed by analytical reverse phase (RP)-HPLC, 50 μL of aSyn was injected onto a Discovery Bio Wide Pore C18-5 column and eluted using a gradient of 5% acetonitrile + 0.1% acetic acid to 95% acetonitrile + 0.1% acetic acid with H_2O + 0.1% acetic acid over 40 minutes at 1 ml/min. Percentage purity of aSyn was 93.9% based on absorbance at 280 nm. (B) Coomassie blue staining of SDS-PAGE gel of WT aSyn. (C) Phosphorylation of $^{13}\text{C}/^{15}\text{N}$ labelled aSyn at S129 was confirmed by mass spectrometry (expected mass 15.333 kDa). (D) Ultra performance liquid chromatography (UPLC) and (E) coomassie blue staining of SDS-PAGE gel was used to determine aSyn purity. The labelling percentage of S129 was 99.89%.

909

910

911

912

913



Figure S2. Peptide coverage map of aSyn using HDX-MS.

Peptide mapping of aSyn was performed on a pepsin column prior to HDX-MS experiments, yielding 100% coverage of aSyn with a high degree (5.38) of redundancy. Peptides were identified by MS-MS fragmentation with ProteinLynx Global Server (Waters).

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933




Figure S3. Deuterium uptake plots, measured in Dalton (Da), for representative peptides containing aar 4-17 (N-terminus) and aar 125-132 (C-terminus) of WT aSyn in the presence (red) and absence (blue) of calcium. Six replicates were collected per condition (+/- calcium) for a 30 s labelling timepoint. Error indicates 1 s.d. No correction was made for back-exchange. Uptake data for all the peptides were collected and further analysed to form Figures 3 and 4.

934

935

936

937

Discussion of ThT assays and FTIR of D to A mutants

Thioflavin T (ThT)-based kinetic assays showed little difference in aggregation rates for D115A, D119A, D121A and WT aSyn in the absence of calcium, but in the presence of calcium the D121A aSyn mutant had a significantly reduced aggregation rate compared to the other aSyn variants (Figure S2). Furthermore, D121A aSyn did not aggregate into fibrillary structures under these conditions as determined by AFM (Figure S3), suggesting that D121A may not bind calcium or had a different, non-aggregation prone monomeric structure. Analysis of the structure by FTIR showed that there were no significant differences in all D to A mutant structures compared to WT, which was overall disordered (Figure S4).

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956




Figure S4. ThT-based aggregation assay reveals that D121A aSyn does not aggregate to the same extent as WT, D115A and D119A upon incubation with calcium.

(A) The average of individual experiments is shown as ThT fluorescence intensity plotted as % of maximum fluorescence per plate of WT (blue), D115A (green), D119A (purple) and D121A aSyn (red) and (B) in the presence of 2.5 mM CaCl₂. 50 μM aSyn was incubated with 10 μM ThT in a 384 well plate with orbital agitation at 300 rpm for 5 minutes before each read every hour for 160 hours. (C.) Remaining monomer was measured using SEC-HPLC, 35 μL of monomer from each well in the ThT assay were analysed on an AdvanceBio SEC 130Å column equilibrated in 20 mM Tris pH 7.2 at 1 mL/min. Remaining monomer concentration was measured from the area under the peak and calculated using a standard curve of known concentrations. The average remaining monomer is numerically shown. (D.) Lag time (T_{lag}) and (E.) time to reach 50 % of maximum aggregation (t₅₀) could only be calculated for assays containing calcium as there was no clear aggregation plateau in aSyn samples without calcium. Measurements were repeated with at least four sample replicates of three experiments and a one-way ANOVA with Sidak's multiple comparison was used to calculate statistical significance. Error bars represent SEM.

957

958

959

960

961

962

963




Figure S5. AFM reveals D121A aSyn forms mostly oligomeric structures, while WT, D115A and D119A aSyn form fibrillary structures upon incubation.

aSyn samples were taken after ThT-based assays and incubated on freshly cleaved mica coated in 0.01% poly-lysine. Samples were washed in dH₂O and dried. Representative images show fibril formation for WT, D115A and D119A aSyn samples, but mostly oligomeric structures formed in D121A aSyn samples. Scale bar = 800 nm.

964

965

966

967

968

969

970

971

972

973




Figure S6. FTIR spectra and secondary structure analysis of WT and D to A mutant aSyn reveal no structural differences between the variants.

69 μ M aSyn in 20 μ M ammonium acetate was lyophilised and analysed using FTIR. (A) FTIR spectra of the absorbance of the aSyn D to A mutants, D115A (green), D119A (purple), D121A (red) and WT aSyn (blue) between 1590 – 1710 cm^{-1} and (B) their respective secondary structure as % distribution after spectra deconvolution. Three scans were performed for each sample and the experiment was repeated twice. A one-way ANOVA with Sidak's multiple comparison was used to calculate statistical significance. Error bars represent SEM.

974

975

976

977

978

979

980

981

982

983

984

985

986




Figure S7. Dissociation constants of WT, pS129 and D121A aSyn and calcium reveal no significant differences between the different variants compared to WT aSyn and cooperative binding of calcium to aSyn.

^1H - ^{15}N HSQC spectra of WT, pS129 and D121A aSyn (200 μM) was collected in the presence of increasing concentrations of Ca^{2+} (0.0 mM to 4.2 mM). (A) Fitting of aSyn calcium binding (K_D), where the number of calcium ions bound is fixed to 3, based on MS data. Calculated K_D were fitted for i) WT, ii) pS129, iii) D121A aSyn. (B) A second fitting was then used which takes into account cooperative binding using the Hill equation and gave K_D values for i) WT, ii) pS129, iii) D121A aSyn. For all fittings using the Hill equation the n values are larger than 1 which shows positive cooperativity for the binding of calcium ions.

987

988

989

990

991

992

993

994




Figure S8. ThT-based aggregation assay reveals that D121A aSyn and pS129 aSyn do not aggregate as fast as WT aSyn.

(A) The average of individual experiments are shown as ThT fluorescence intensity plotted as % of maximum fluorescence per plate of WT (blue), D121A (red) and pS129 aSyn (yellow) and (B) in the presence of 2.5 mM CaCl₂. 20 µM aSyn was incubated with 20 µM in a half area 96 well plate with orbital agitation at 300 rpm for 5 minutes before each read every hour for 150 hours. (C.) Remaining monomer was measured using SEC-HPLC, 35 µL of monomer from each well in the ThT assay were analysed on an AdvanceBio SEC 130Å column equilibrated in 20 mM Tris pH 7.2 at 1 mL/min. Remaining monomer concentration was measured from the area under the peak and calculated using a standard curve of known concentrations. The average remaining monomer is numerically shown. (D.) Lag time (T_{lag}) and (E.) time to reach 50 % of maximum aggregation (t₅₀) were calculated and the average numerically shown. Measurements were repeated with at least four sample replicates of three experiments and a one-way ANOVA with Sidak's multiple comparison was used to calculate statistical significance. Error bars represent SEM.

995

996

997

998

999

1000

1001




Figure S9. Representative chromatograph of the remaining aSyn monomer concentration as determined at the end of the ThT-based assay and analysed by size exclusion chromatography.

aSyn samples taken from the wells of ThT-based assays were centrifuged to remove fibrils and 35 μ L of the remaining monomer was analysed by HPLC-SEC. 35 μ L was injected on to an AdvanceBio SEC 130 \AA column at a flow rate of 1 ml/min in 20 mM Tris pH 7.2 and absorbance measured at 280 nm. The area under the curve reflects the remaining monomer concentration, which is calculated using known protein standards. Representative remaining monomer concentration from one well of WT aSyn (black) and WT aSyn + 2.5 mM CaCl₂ (blue) is shown.

1002

1003

1004

1005

1006

1007

1008

1009


1010

1011

1012

1013

1014



1015

1016

1017

Figure S10. ThT-based aggregation assay reveals that the aSyn familial mutants display different aggregation behaviour upon the addition of calcium.

(A) The average of individual experiments are shown as ThT fluorescence intensity plotted as % of maximum fluorescence per plate of WT (red), A30P (orange), A53T (yellow), E46K (green), A53E (blue), H50Q (lavender), G51D aSyn (purple) and (B) in the presence of 2.5 mM CaCl₂. 20 μM aSyn was incubated with 20 μM in a half area 96 well plate with orbital agitation at 300 rpm for 5 minutes before each read every hour for 150 hours. (C.) Remaining monomer was measured using SEC-HPLC, 35 μL of monomer from each well in the ThT assays were analysed on an AdvanceBio SEC 130Å column equilibrated in 20 mM Tris pH 7.2 at 1 mL/min. Remaining monomer concentration was measured from the area under the peak and calculated using a standard curve of known concentrations. The average remaining monomer is numerically shown. (D.) Lag time (T_{lag}) and (E.) time to reach 50 % of maximum aggregation (t_{50}) were calculated and the average numerically shown. Mutant G51D aSyn did not reach the elongation phase in the studied timeframe, so the t_{50} value was not calculated. Measurements were repeated with at least four sample replicates of three experiments and a one-way ANOVA with Sidak's multiple comparison was used to calculate statistical significance. Error bars represent SEM.

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033




Figure S11. FTIR spectra and secondary structure analysis of monomeric WT aSyn and aSyn familial mutants reveal structural differences between the aSyn variants.

69 μ M aSyn in 20 μ M ammonium acetate was lyophilised and analysed using FTIR. (A) FTIR spectra of the absorbance of WT aSyn (blue) and the aSyn familial mutants, A30P (red), E46K (yellow), H50Q (teal), G51D (orange), A53T (green), A53E aSyn (purple) between 1590 – 1710 cm^{-1} and (B) their respective secondary structure as % distribution after spectra deconvolution. Three scans were performed for each sample and the experiments were repeated twice. A one-way ANOVA with Sidak's multiple comparison was used to calculate statistical significance, for which $p < 0.05$ * and $p < 0.01$ **. Error bars represent SEM.

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

The % distribution of conformations was quantified by calculating the area under the curve for each peak in the chromatograph based on drift time (Figure 4b, Table S1, S2). It is likely that many conformations are present in each designated A-E conformation region as observed by the shoulders present in each peak as different conformations are not resolved (Figure S12)




Figure S12. Arrival time distribution (ATD) of aSyn conformations.

The average percentage distribution of the conformations was determined by identifying peaks in the ATD. Each peak was designated a letter A-E dependent on ATD (represented for WT aSyn). ATD is shown for WT, A30P, E46K, H50Q, G51D, A53E and A53T.

47




Table S1. Average percentage of the distribution of conformations of WT aSyn and mutants determined by nano-ESI-IM-MS in the absence calcium shows small changes in percentage distribution of conformations between the aSyn and its variants.

Conformation without calcium	WT av. %	A30P av. %	E46K av. %	A53E av. %	A53T av. %	H50Q av. %	G51D av. %
A	23.54	21.86	26.22*	27.29	26.57*	25.96	28.05
B	26.80	26.48	27.72	24.97	26.78	30.47	24.92
C	33.09	35.74*	29.46**	34.38	32.88	30.26	30.49*
D	15.58	14.83	15.74	12.12**	12.62**	12.37*	14.38
E	0.98	1.10	0.85	1.20	1.10	0.92	2.14

Table S2. Average percentage of the distribution of conformations of WT and aSyn mutants determined by nano-ESI-IM-MS in the presence of calcium shows significant differences upon the addition of calcium to aSyn and its variants.

Conformation with calcium	WT av. %	A30P av. %	E46K av. %	A53E av. %	A53T av. %	H50Q av. %	G51D av. %
A	21.53	22.79	25.82*	24.18	25.40*	24.86	25.00
B	14.73	19.96**	17.54**	15.39	18.66**	17.74**	16.06
C	37.85	37.57	32.74*	39.04	38.66	37.74	36.16
D	22.83	17.57*	21.58	18.93*	15.96**	18.06	20.10
E	3.07	2.10*	2.32	2.45	1.84*	2.16	2.68

*p<0.05

**p<0.01

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058




Figure S14. Analysis of number of Ca²⁺ ions bound to different aSyn mutants at different protein to calcium ratios reveals no significant differences between the different aSyn variants.

The number of calcium ions bound to 20 μ M of aSyn in 20 mM ammonium acetate at a protein to calcium ratio of 1:10 (blue) 1:20 (orange) and 1:50 (red) was determined from the mass of the different metallated species in the native nano ESI-MS spectra.

1059

1060

1061

1062

1063

1064




Figure S15. Native nano ESI-MS spectra of WT aSyn with increasing concentrations of calcium shows that up to 11 calcium ions can be bound to aSyn at a 1:250 protein to calcium ratio.

(A) The native nano ESI-MS full spectrum of WT aSyn with calcium in ratios 1:1, 1:5, 1:10, 1:50, 1:100 and 1:250. (B) The zoomed in 8+ charge state of aSyn shows that at least 11 calcium ions can be bound to aSyn in a 1:250 protein to calcium ratio. 20 μM aSyn in 20 mM ammonium acetate (pH 7) was used in all experiments.

Methods and Materials for Supplementary Data

Thioflavin-T (ThT) based assays

10 μM freshly made ThT (abcam, Cambridge, UK) was added to 50 μL of 10 μM aSyn in 20 mM Tris pH 7.2. All samples were loaded onto nonbinding, clear bottom, 96-well half-area plates (Greiner Bio-One GmbH, Germany). The plates were sealed with a SILVERseal aluminium microplate sealer (Grenier Bio-One GmbH). Fluorescence measurements were taken with a FLUOstar Omega plate reader (BMG LABTECH GmbH, Ortenberg, Germany). The plates were incubated at 37°C with orbital shaking at 300 rpm for five minutes before each read every hour. Excitation was set at 440 nm with 20 flashes and the ThT fluorescence intensity measured at 480 nm emission with a 1300 gain setting. ThT assays were repeated at least 3 times using four or more wells for each condition. Data were normalised to the well with the maximum fluorescence intensity for each plate and the average fluorescence intensity was calculated for all experiments. The lag time (t_{lag}) and half life of the fluorescence (t₅₀) were calculated for each aSyn variant.

Analytical Size Exclusion Chromatography (SEC) of remaining monomer after ThT assays

SEC-HPLC analysis was used to calculate the remaining aSyn monomer concentration in each well at the end of the ThT assays. The contents of each well after the ThT-based assay were centrifuged at 21k x g for 20 minutes and the supernatant added to individual aliquots in the autosampler of the Agilent 1260 Infinity HPLC system (Agilent Technologies LDA UK Limited, UK). 35 μL of each sample was injected onto an Advance Bio SEC column, 7.8 x 300 mm 300Å (Agilent, UK) in 20 mM Tris pH 7.2 at 1 mL/min flow-rate. The elution profile was monitored by UV absorption at 220 and 280 nm. A calibration curve of known concentrations of aSyn was used to calculate the remaining monomer concentration of aSyn in each well. Two or three wells per experiment for three experiments were analysed for the remaining monomer concentration.

Fourier transform infrared spectroscopy (FTIR)

To prepare samples for FTIR analysis, aSyn monomer was buffer exchanged into 20 mM ammonium acetate pH 7 using PD10 Desalting columns (GE Healthcare). The samples were snap frozen in liquid nitrogen and lyophilised in a LyoQuest 85 freeze-dryer (Telstar, Spain). ~300 μg protein was mixed with ~100 mg KBr using an agate mortar and pressed to 10 tonnes to form self-supporting disks. The FTIR spectra were collected on a Cary 680 FTIR spectrometer with 60 scans and a resolution of 1 cm^{-1} . The FTIR spectra were plotted by subtracting the KBr background spectrum, performing a spline baseline correction, and normalising the spectra to the area under the curve.

Atomic Force Microscopy (AFM)

The contents of wells from the ThT-based assays were centrifuged for 20 minutes at 21 k x g. The supernatant was removed to keep 10 μL with remaining fibrils. The fibrils were resuspended and incubated on a freshly cleaved mica surface, which had been coated in 0.1% poly-l-lysine, for 20 min. The mica was washed three times in 18.2 Ω dH₂O to remove loose protein. Images were acquired in dH₂O using tapping mode on a BioScope Resolve (Bruker, AXS GmbH) using ScanAsyst-Fluid+ probes. 512 lines were acquired at a scan rate of 1.5-2 Hz per image with a field of view of 2-5 μm and for at least six fields of view. Images were adjusted for contrast and exported from NanoScope Analysis 8.2 software (Bruker).